Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3908 |
Name | lung non-small cell carcinoma |
Definition | A lung carcinoma that is characterized as any type of epithelial lung cancer other than small cell lung carcinoma. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA act mut | Pictilisib | lung non-small cell carcinoma | sensitive | detail... |
PTEN del | PF-04691502 | lung non-small cell carcinoma | predicted - sensitive | detail... |
PTEN loss | Pictilisib | lung non-small cell carcinoma | sensitive | detail... |
BRAF Y472C | Dasatinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V | Dasatinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | Vemurafenib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib | lung non-small cell carcinoma | sensitive | detail... |
TP53 P72R | Cisplatin + Irinotecan | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion ALK S1206Y | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
PIK3CA E545K | Copanlisib + Paclitaxel | lung non-small cell carcinoma | sensitive | detail... |
RET act mut | Ponatinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Belizatinib | lung non-small cell carcinoma | no benefit | detail... |
ALK positive | Ensartinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1269A | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK G1269A | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Ensartinib + Sirolimus | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1202R | Ceritinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK V1180L | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
PIK3CA mutant | PWT33597 | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
CDKN2A loss | Palbociclib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion | Alectinib | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion | Brigatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M | Brigatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y | Ceritinib | lung non-small cell carcinoma | conflicting | detail... |
NRAS Q61K | Gedatolisib | lung non-small cell carcinoma | decreased response | detail... |
TP53 R158G | Gedatolisib | lung non-small cell carcinoma | sensitive | detail... |
STK11 mutant | Gedatolisib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1269A | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK I1171T | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Ceritinib + Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK mut | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK V1180L | Alectinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK V1180L | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Brigatinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Alectinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Ensartinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | TAE226 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G469A | TAE226 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V | TAE226 | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | Zoligratinib | lung non-small cell carcinoma | sensitive | detail... |
TP53 R248W | APR-246 + Cisplatin | lung non-small cell carcinoma | sensitive | detail... |
TP53 R273H | APR-246 + Cisplatin | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1269A | Alectinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | Navitoclax + Vemurafenib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | Navitoclax + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | Trametinib + TW-37 | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | TW-37 + Vemurafenib | lung non-small cell carcinoma | sensitive | detail... |
TP53 wild-type | CEP-8983 + Cisplatin | lung non-small cell carcinoma | sensitive | detail... |
TP53 mutant | CEP-8983 + Cisplatin | lung non-small cell carcinoma | sensitive | detail... |
BRAF L485_P490delinsY | LY3009120 | lung non-small cell carcinoma | sensitive | detail... |
BRAF L485_P490delinsY | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF L485_P490delinsY | Dabrafenib | lung non-small cell carcinoma | resistant | detail... |
ROS1 rearrange | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK I1171S | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ATM loss | Ceralasertib + Cisplatin | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Entrectinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK C1156Y | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y | Luminespib | lung non-small cell carcinoma | no benefit | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Crizotinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Alectinib | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 fusion | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion ALK G1202R | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | Fexagratinib | lung non-small cell carcinoma | sensitive | detail... |
RET fusion | Vandetanib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange ALK neg | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
ALK mutant | Crizotinib + Onalespib | lung non-small cell carcinoma | no benefit | detail... |
CD274 positive | Pembrolizumab | lung non-small cell carcinoma | sensitive | detail... |
BRAF L485Y | GDC0879 | lung non-small cell carcinoma | resistant | detail... |
BRAF wild-type | GDC0879 | lung non-small cell carcinoma | resistant | detail... |
BRAF L597V NRAS Q61K | AZ628 | lung non-small cell carcinoma | sensitive | detail... |
BRAF L597V NRAS Q61K | TAK-632 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V | TAK-632 | lung non-small cell carcinoma | sensitive | detail... |
BRAF L597V NRAS Q61K | PLX7904 | lung non-small cell carcinoma | decreased response | detail... |
BRAF L597V NRAS Q61K | Vemurafenib | lung non-small cell carcinoma | decreased response | detail... |
BRAF G466V | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
BRAF L597V NRAS Q61K | Dabrafenib | lung non-small cell carcinoma | decreased response | detail... |
TP53 wild-type | KRT-232 | lung non-small cell carcinoma | sensitive | detail... |
TP53 wild-type | Cisplatin + KRT-232 | lung non-small cell carcinoma | sensitive | detail... |
TP53 wild-type | Carboplatin + KRT-232 | lung non-small cell carcinoma | sensitive | detail... |
NRAS Q61K | Pimasertib | lung non-small cell carcinoma | sensitive | detail... |
NRAS Q61K | Everolimus + Pimasertib | lung non-small cell carcinoma | sensitive | detail... |
NRAS Q61K | Pimasertib + Sorafenib | lung non-small cell carcinoma | sensitive | detail... |
NRAS Q61K | Pimasertib + Regorafenib | lung non-small cell carcinoma | sensitive | detail... |
PIK3CA mutant | PF-04691502 | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | PRN1371 | lung non-small cell carcinoma | sensitive | detail... |
FGFR2 amp | PRN1371 | lung non-small cell carcinoma | sensitive | detail... |
FGFR3 amp | PRN1371 | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Nivolumab | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Pembrolizumab | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Durvalumab | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Atezolizumab | lung non-small cell carcinoma | no benefit | detail... |
FGFR1 amp | RO4987655 | lung non-small cell carcinoma | no benefit | detail... |
FGFR1 amp | RO5126766 | lung non-small cell carcinoma | no benefit | detail... |
FGFR1 amp | Selumetinib | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange ALK E1210K | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange MAP2K1 K57N | Ceritinib + Selumetinib | lung non-small cell carcinoma | sensitive | detail... |
PIK3CA G118D | LY3023414 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Afatinib + Alectinib | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | E7090 | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | NGI-1 | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK | Brigatinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF G469A | Dabrafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF mutant | Dabrafenib + Trametinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G469V | Sorafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G469A | Vemurafenib | lung non-small cell carcinoma | resistant | detail... |
BRAF G469A | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF G469A | Trametinib + Vemurafenib | lung non-small cell carcinoma | conflicting | detail... |
ROS1 rearrange | NPS-1034 | lung non-small cell carcinoma | sensitive | detail... |
STK11 inact mut | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
STK11 Q37* | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
STK11 E199* | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
STK11 W332* | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
STK11 dec exp | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
STK11 K48fs | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 fusion | Taletrectinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK positive | Entrectinib | lung non-small cell carcinoma | sensitive | detail... |
RET rearrange | Alectinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK I1171N | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK G1202R | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ROS1 rearrange | Entrectinib | lung non-small cell carcinoma | sensitive | detail... |
STK11 E57fs | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK F1245C | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1245C | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
RET rearrange | Cabozantinib | lung non-small cell carcinoma | sensitive | detail... |
RET rearrange | Vandetanib | lung non-small cell carcinoma | sensitive | detail... |
RET rearrange | Sunitinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET rearrange | RXDX-105 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
TP53 mutant | Pembrolizumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 rearrange | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
PIK3CA H1047X | Taselisib | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | GSK3052230 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V NRAS Q61K | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF mutant | KO-947 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G466V | Dabrafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
TP53 negative | Seliciclib | lung non-small cell carcinoma | decreased response | detail... |
TP53 R175H | Seliciclib | lung non-small cell carcinoma | resistant | detail... |
TP53 S215G | Seliciclib | lung non-small cell carcinoma | resistant | detail... |
TP53 Y220C | Seliciclib | lung non-small cell carcinoma | resistant | detail... |
TP53 P98A | Seliciclib | lung non-small cell carcinoma | decreased response | detail... |
TP53 A159V | Seliciclib | lung non-small cell carcinoma | decreased response | detail... |
TP53 Y234C | Seliciclib | lung non-small cell carcinoma | decreased response | detail... |
TP53 wild-type | Seliciclib | lung non-small cell carcinoma | sensitive | detail... |
NRAS mutant | KO-947 | lung non-small cell carcinoma | predicted - sensitive | detail... |
STK11 mutant | unspecified PD-1 antibody | lung non-small cell carcinoma | decreased response | detail... |
BRAF mutant | unspecified PD-1 antibody | lung non-small cell carcinoma | predicted - sensitive | detail... |
FGFR1 amp NRAS amp | Infigratinib | lung non-small cell carcinoma | resistant | detail... |
FGFR1 amp NRAS amp | Trametinib | lung non-small cell carcinoma | resistant | detail... |
FGFR1 amp NRAS amp | Infigratinib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp NRAS over exp | Infigratinib | lung non-small cell carcinoma | decreased response | detail... |
FGFR1 amp NRAS over exp | Infigratinib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | Infigratinib | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | Infigratinib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Crizotinib + Filgotinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK F1174V | Alectinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171S ALK F1174V | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK I1171T | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK I1171N | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1174V | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK L1152R | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1269A | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK T1151dup ALK G1269A | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK amp | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK G1202R | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK | CEP-28122 | lung non-small cell carcinoma | sensitive | detail... |
ALK negative | CEP-28122 | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK L1196M | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK S1206Y | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK C1156Y | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ROS1 rearrange | Alectinib | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Erlotinib | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Gefitinib | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Afatinib | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Osimertinib | lung non-small cell carcinoma | no benefit | detail... |
ROS1 rearrange | Erlotinib | lung non-small cell carcinoma | no benefit | detail... |
ROS1 rearrange | Gefitinib | lung non-small cell carcinoma | no benefit | detail... |
ROS1 rearrange | Afatinib | lung non-small cell carcinoma | no benefit | detail... |
ROS1 rearrange | Osimertinib | lung non-small cell carcinoma | no benefit | detail... |
EML4 - ALK ALK F1174V ALK G1202R | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK F1174C | Ceritinib | lung non-small cell carcinoma | resistant | detail... |
CD274 pos STK11 mut | unspecified PD-1 antibody | lung non-small cell carcinoma | predicted - resistant | detail... |
BRAF act mut | RAF709 | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK I1171N ALK L1198F | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK I1171N ALK D1203N | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK C1156Y ALK L1198F | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK L1196M ALK G1202R | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK G1202R ALK L1204V ALK G1269A | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK D1203N ALK E1210K ALK G1269A | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
RET fusion | Selpercatinib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 fusion ROS1 L1951R ROS1 L2026M | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ROS1 fusion ROS1 L1951R ROS1 L2026M | Ceritinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK E1210K | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK S1206C ALK E1210K | Brigatinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK F1174L ALK L1198V | Brigatinib | lung non-small cell carcinoma | resistant | detail... |
ROS1 fusion KIT D816G | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK FGFR1 amp | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK HRAS amp | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
BRAF G469A | Encorafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF G469A | Dabrafenib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK G1202R | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171N | Brigatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK I1171T | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK V1180L | Brigatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK V1180L | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171T | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK V1180L ALK L1196M ALK G1202R | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK D1203N | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
KEAP1 mutant | Radiotherapy | lung non-small cell carcinoma | predicted - resistant | detail... |
BRAF D594N | RMC-4550 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF N581D | RMC-4550 | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET rearrange | Ponatinib | lung non-small cell carcinoma | no benefit | detail... |
FGFR1 V561M | Fexagratinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange TP53 mut | Crizotinib | lung non-small cell carcinoma | decreased response | detail... |
ALK rearrange TP53 mut | Ceritinib | lung non-small cell carcinoma | decreased response | detail... |
ALK rearrange TP53 mut | Alectinib | lung non-small cell carcinoma | decreased response | detail... |
ALK rearrange TP53 mut | Brigatinib | lung non-small cell carcinoma | decreased response | detail... |
STK11 mutant | unspecified PD-L1 antibody | lung non-small cell carcinoma | decreased response | detail... |
BRAF mutant | unspecified PD-L1 antibody | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK G1202R ALK G1269A | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
CDKN2A negative | Palbociclib | lung non-small cell carcinoma | predicted - sensitive | detail... |
CDKN2A negative | Everolimus + Palbociclib | lung non-small cell carcinoma | sensitive | detail... |
CDKN2A negative | Palbociclib + Sirolimus | lung non-small cell carcinoma | sensitive | detail... |
CDKN2A negative | Palbociclib + PF-04691502 | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion ALK G1202R KIT amp | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK | Iruplinalkib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600X | Dabrafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E/K | Dabrafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600K | Dabrafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange | Brigatinib | lung non-small cell carcinoma | no benefit | detail... |
CDKN2A inact mut | Palbociclib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 fusion | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | MTI-31 | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange TP53 mut | Crizotinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 rearrange PIK3CA E545K | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ROS1 rearrange ROS1 L2026M TP53 P278H | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CD274 over exp | Pembrolizumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 over exp | Atezolizumab | lung non-small cell carcinoma | sensitive | detail... |
CD274 over exp | Nivolumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 over exp | Ipilimumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
TP53 mutant | Nivolumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
TP53 mutant | Ipilimumab + Nivolumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK G1202R | Ceritinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK G1202R | Ensartinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171X | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171X | Ceritinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171X | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171X | Ensartinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M | Ceritinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M | Ensartinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK G1202R | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK D1203N | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174C | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174L | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171X | Lorlatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 fusion | Entrectinib | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | SL-279252 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK E1303K | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK fusion | Ensartinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Ensartinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | PLB1003 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ATM del | AZD7648 + Olaparib | lung non-small cell carcinoma | sensitive | detail... |
ATM del | AZD7648 | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK F1174C ALK G1202R | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174L ALK G1202R | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK T1151M ALK G1202R | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CD274 positive | Nivolumab | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Crizotinib + Onalespib | lung non-small cell carcinoma | no benefit | detail... |
ALK C1156Y ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK F1174V ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK F1174L ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK L1196M ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK G1202R ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK I1171T ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK I1171S ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK L1152R ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK amp ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK L1152V ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
FGFR1 amp | Zotatifin | lung non-small cell carcinoma | sensitive | detail... |
ATM del | Olaparib | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Atezolizumab + Carboplatin + Nab-paclitaxel | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600X | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600D | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600M | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600K | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF N581S | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
BRAF K601E | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
BRAF K601N | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
BRAF G466A | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
BRAF G469V | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
BRAF G596R | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
TP53 R175H | SLMP53-2 | lung non-small cell carcinoma | sensitive | detail... |
TP53 Y220C | SLMP53-2 | lung non-small cell carcinoma | sensitive | detail... |
TP53 G245S | SLMP53-2 | lung non-small cell carcinoma | sensitive | detail... |
PIK3CA mutant | Sulindac | lung non-small cell carcinoma | predicted - sensitive | detail... |
PIK3CA act mut | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
PTEN inact mut | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
NRAS act mut | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
BRAF act mut | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CTNNB1 act mut | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CTNNB1 S37F | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CTNNB1 S37C | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CTNNB1 D32V | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CTNNB1 G34V | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CTNNB1 T41I | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
TP53 mutant | Osimertinib | lung non-small cell carcinoma | not predictive | detail... |
TP53 inact mut | Osimertinib | lung non-small cell carcinoma | not predictive | detail... |
ARID1A mutant | unspecified PD-L1 antibody | lung non-small cell carcinoma | predicted - sensitive | detail... |
ARID1A mutant | unspecified PD-1 antibody | lung non-small cell carcinoma | predicted - sensitive | detail... |
PIK3CA amp | Sulindac | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 positive | Atezolizumab + Tiragolumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET fusion | Pralsetinib | lung non-small cell carcinoma | sensitive | detail... |
RET rearrange | Selpercatinib | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Cisplatin + Pembrolizumab + Pemetrexed Disodium | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Carboplatin + Pembrolizumab + Pemetrexed Disodium | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange | Taletrectinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK mutant | Belizatinib | lung non-small cell carcinoma | no benefit | detail... |
ALK amp | Belizatinib | lung non-small cell carcinoma | no benefit | detail... |
STK11 loss | Vistusertib | lung non-small cell carcinoma | no benefit | detail... |
FGFR2 V514L | Fexagratinib | lung non-small cell carcinoma | no benefit | detail... |
FGFR3 P573S | Fexagratinib | lung non-small cell carcinoma | no benefit | detail... |
FGFR3 S756P | Fexagratinib | lung non-small cell carcinoma | no benefit | detail... |
CD274 positive | Nivolumab + Pegilodecakin | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 amp | Nivolumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET rearrange | Pralsetinib | lung non-small cell carcinoma | sensitive | detail... |
ARID1A inact mut | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | unknown | detail... |
PIK3CA E545K | T-2143 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G596V | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
NRAS Q61K | BI-3406 | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1196Q | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1196Q | Brigatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E | Pembrolizumab | lung non-small cell carcinoma | not predictive | detail... |
BRAF V600E | Nivolumab | lung non-small cell carcinoma | not predictive | detail... |
BRAF mut CD274 pos | Pembrolizumab | lung non-small cell carcinoma | not predictive | detail... |
BRAF mut CD274 pos | Nivolumab | lung non-small cell carcinoma | not predictive | detail... |
BRAF mut CD274 pos | Atezolizumab | lung non-small cell carcinoma | not predictive | detail... |
BRAF V600E | Atezolizumab | lung non-small cell carcinoma | not predictive | detail... |
BRAF mutant | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | unknown | detail... |
BRAF amp | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | not predictive | detail... |
BRAF V600E | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | unknown | detail... |
RET fusion | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | unknown | detail... |
ROS1 fusion | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | unknown | detail... |
RET mutant | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | unknown | detail... |
ALK positive | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
KEAP1 dec exp | Radiotherapy + Telaglenastat | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E FGFR2 A553D | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E PIK3CA E545K | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 over exp | Cemiplimab | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Ipilimumab + Nivolumab | lung non-small cell carcinoma | no benefit | detail... |
EML4 - ALK ALK I1171N | Gilteritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK I1171N | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK I1171N | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK I1171N | Entrectinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Gilteritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK TP53 Q331* | Alectinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK TP53 Q331* | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK TP53 V274fs | Alectinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK TP53 V274fs | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK TP53 Q331* | Alectinib + Ixazomib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK TP53 V274fs | Alectinib + Ixazomib | lung non-small cell carcinoma | sensitive | detail... |
CD274 dec exp | Avelumab + Pepinemab | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 positive | Durvalumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 over exp | Retifanlimab | lung non-small cell carcinoma | predicted - sensitive | detail... |
TP53 Q331* | AZ32 + Radiotherapy | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Alectinib + SHP099 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Alectinib + Selumetinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Alectinib + RMC-4550 | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion ALK T1151dup | Ceritinib | lung non-small cell carcinoma | no benefit | detail... |
ALK fusion ALK T1151dup | Lorlatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 positive | Ipilimumab + Nivolumab | lung non-small cell carcinoma | sensitive | detail... |
KEAP1 D236H | Gefitinib | lung non-small cell carcinoma | resistant | detail... |
KEAP1 D236H | Afatinib | lung non-small cell carcinoma | resistant | detail... |
KEAP1 D236H | Osimertinib | lung non-small cell carcinoma | resistant | detail... |
CDKN2A inact mut | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | not predictive | detail... |
CDKN2A del | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | not predictive | detail... |
CD274 positive | Anlotinib + Cadonilimab | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 positive | Atezolizumab | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Durvalumab + Vactosertib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 fusion ROS1 S1986F ROS1 L2000V | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CD274 over exp | Niraparib + Pembrolizumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 positive | Niraparib + Pembrolizumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 rearrange | Repotrectinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK G1202del | Lorlatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK F1174X | Lorlatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK G1269A | Lorlatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK | XMU-MP-5 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK L1196M ALK G1202R | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ROS1 rearrange | Crizotinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
NRAS Q61K | Lifirafenib + PD-0325901 | lung non-small cell carcinoma | sensitive | detail... |
NRAS Q61K | Lifirafenib + Pimasertib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Iruplinalkib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange | Iruplinalkib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Ceritinib + Ribociclib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK G1202R | Ceritinib + HJC0152 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1202R | HJC0152 | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | CPL304110 | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | LTT462 + LXH 254 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF K601N | LTT462 + LXH 254 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G466A | LTT462 + LXH 254 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange | Foritinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion ALK C1156Y ALK L1198F | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK fusion ALK L1196M ALK G1202R | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK fusion ALK G1202R ALK L1204V ALK G1269A | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK fusion ALK D1203N ALK E1210K ALK G1269A | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK fusion ALK G1202R ALK S1206F ALK G1269A | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ROS1 fusion ROS1 G2032R | Taletrectinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion | TQ-B3139 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | TQ-B3139 | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | MT-6402 | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK | APG-2449 | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK L1196Q | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK E1129V | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK amp | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171S | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174L | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174V | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174S | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK E1129V | Ceritinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171T ALK F1174V | Ceritinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E BRAF K601_W604del | Dabrafenib + Trametinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion | APG-2449 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 fusion | NUV-520 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 fusion ROS1 G2032R | NUV-520 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange | Conteltinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1202R | NVL-655 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK T1151M ALK G1202R | NVL-655 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1202R | NVL-655 | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 over exp | Cetrelimab | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK positive | Brigatinib | lung non-small cell carcinoma | no benefit | detail... |
ALK V1180L | Brigatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK V1180Y | Brigatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171T ALK G1269A | Brigatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 positive | Carboplatin + Cemiplimab + Paclitaxel | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Cemiplimab + Cisplatin + Paclitaxel | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Carboplatin + Cemiplimab + Pemetrexed Disodium | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Cemiplimab + Cisplatin + Pemetrexed Disodium | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | lung non-small cell carcinoma | sensitive | detail... |
ATM Q1919P | RP-3500 | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange | Carboplatin + Pembrolizumab + Pemetrexed Disodium | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 rearrange | Carboplatin + Paclitaxel + Pembrolizumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 positive | Surufatinib + Toripalimab-tpzi | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E | Lifirafenib + PD-0325901 | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET fusion | HS-10365 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E | Binimetinib + Encorafenib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Lorlatinib + PF-07284892 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1202R | Lorlatinib + PF-07284892 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 fusion | Repotrectinib | lung non-small cell carcinoma | sensitive | detail... |
CD274 positive | AZD2936 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ATM Q1331H ATM I1441fs | Radiotherapy | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G466V | IHMT-RAF-128 | lung non-small cell carcinoma | sensitive | detail... |
BRAF L597V NRAS Q61K | IHMT-RAF-128 | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange | TQ-B3101 | lung non-small cell carcinoma | sensitive | detail... |
ROS1 fusion | TQ-B3139 | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 pos STK11 mut | Pembrolizumab | lung non-small cell carcinoma | not predictive | detail... |
CD274 pos KEAP1 mut | Pembrolizumab | lung non-small cell carcinoma | not predictive | detail... |
ALK rearrange | TQ-B3139 | lung non-small cell carcinoma | sensitive | detail... |
PBRM1 mutant | unspecified PD-1 antibody | lung non-small cell carcinoma | predicted - resistant | detail... |
PBRM1 mutant | unspecified PD-L1 antibody | lung non-small cell carcinoma | predicted - resistant | detail... |
BRAF V600X | Tunlametinib + Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 over exp | IO102-IO103 + Pembrolizumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 fusion ROS1 G2032R | Repotrectinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET amp | Selpercatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET mutant | EP0031 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G469A | SIJ777 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V | SIJ777 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK T1151M | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK L1152V ALK G1269A | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK E1210K | Ensartinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK S1206F | Ensartinib | lung non-small cell carcinoma | predicted - resistant | detail... |
BRAF L485_P490delinsY | LXH 254 | lung non-small cell carcinoma | sensitive | detail... |
BRAF L485_P490delinsY | Encorafenib | lung non-small cell carcinoma | decreased response | detail... |
BRAF L485_P490delinsY | Sorafenib | lung non-small cell carcinoma | sensitive | detail... |
BRAF L485_P490delinsY | Ulixertinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF L485_P490delinsY | LXH 254 + Trametinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF L485_P490delinsY | Sorafenib + Trametinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange | Ficonalkib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Afatinib + Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y | Afatinib + Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK I1171T ALK L1198F | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK C1156Y ALK I1171T ALK L1198F | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK I1171T ALK L1198F | Afatinib + Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK G1202R | Ficonalkib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ATM inact mut | Ceralasertib + Durvalumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
FGFR2 amp | CPL304110 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Brigatinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK L1196P | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1198R | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK C1235R ALK C1237Y | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
FGFR2 fusion | ABSK061 | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 over exp | Necitumumab + Pembrolizumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 over exp | PDC*lung01 + Pembrolizumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
ATM mutant | M1774 | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 positive | Cemiplimab | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G469A | PF-07799933 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V | PF-07799933 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E NRAS Q61K | PF-07799933 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK L1196M ALK G1202R | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK P1094H | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1196Q | Ceritinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK | NVL-655 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M | NVL-655 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK T1151M ALK G1202R | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Ceritinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK T1151M ALK G1202R | Ceritinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Alectinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK T1151M ALK G1202R | Alectinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK T1151M ALK G1202R | Brigatinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK T1151M ALK G1202R | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
BRAF V600X | Cobimetinib + Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion | NVL-655 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion ALK G1202R | NVL-655 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ATM inact mut | RP-3500 | lung non-small cell carcinoma | predicted - sensitive | detail... |
CD274 over exp | PF-06801591 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 rearrange | Foritinib | lung non-small cell carcinoma | sensitive | detail... |
RET fusion | SY-5007 | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Deulorlatinib | lung non-small cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00150657 | Phase II | Bevacizumab + Carboplatin + Gemcitabine | Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer | Unknown status | USA | 0 |
NCT00254319 | Phase II | Carboplatin Bevacizumab + Pemetrexed Disodium | Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) | Unknown status | USA | 0 |
NCT00313599 | Phase I | Lapatinib + Paclitaxel | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT00547105 | Phase II | Erlotinib | Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer | Completed | USA | 0 |
NCT00569296 | Phase I | Aldesleukin + EGFRBi-armed autologous activated T cells + Sargramostim | Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT00585195 | Phase I | Crizotinib + Itraconazole Crizotinib + Rifampin | A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001) | Completed | USA | AUS | 2 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00828009 | Phase II | Cyclophosphamide Bevacizumab Paclitaxel Emepepimut-S Carboplatin | BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT00932451 | Phase II | Crizotinib | An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene | Completed | USA | SWE | POL | NLD | ITA | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BGR | AUS | 6 |
NCT00950365 | Phase II | Erlotinib + Pemetrexed Disodium Pemetrexed Disodium | Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT00975767 | Phase Ib/II | Docetaxel + Glesatinib Erlotinib + Glesatinib | A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT00978250 | Phase II | 5-Fluoro-2-deoxycytidine + Tetrahydrouridine | A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) | Completed | USA | 0 |
NCT00979212 | Phase II | Panitumumab Carboplatin + Paclitaxel | Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10) | Completed | USA | 0 |
NCT00996892 | Phase I | Cobimetinib + Pictilisib | Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT00997334 | Phase II | Erlotinib | Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC | Completed | USA | 0 |
NCT01005797 | Phase I | Panobinostat + Sorafenib | Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | Completed | USA | 0 |
NCT01014598 | Phase I | Cisplatin | Cisplatin in Treating Patients With Lung Cancer | Completed | USA | 0 |
NCT01059552 | Phase I | Vorinostat | Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT01061788 | Phase I | Everolimus + Ganitumab + Panitumumab | A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer | Completed | USA | 0 |
NCT01107626 | Phase III | Pemetrexed Disodium Bevacizumab | Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | GBR | FRA | ESP | 0 |
NCT01179269 | Phase II | Paclitaxel + Pazopanib | Stage IIIB/IV Non-Small Cell Lung Cancer | Withdrawn | 0 | |
NCT01210378 | Phase II | Nitroglycerin | Nitroglycerin in Non-small Cell Lung Cancer | Terminated | NLD | 0 |
NCT01233687 | Phase Ib/II | Rilotumumab Erlotinib | AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01248247 | Phase I | Erlotinib MK2206 + Selumetinib Sorafenib Erlotinib + MK2206 | BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study | Completed | USA | 0 |
NCT01263782 | Phase II | Bevacizumab Carboplatin + Pemetrexed Disodium Cixutumumab | BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer | Completed | USA | 0 |
NCT01288430 | Phase I | DS-2248 | A Study of DS-2248, in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01292655 | Phase I | BMS-906024 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT01306045 | Phase II | Erlotinib Lapatinib MK2206 Sunitinib Selumetinib | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | Completed | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | ITA | FRA | AUS | 1 |
NCT01325441 | Phase Ib/II | Napabucasin + Paclitaxel | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | Completed | USA | CAN | 0 |
NCT01327612 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab | Open Label Extension Study of Conatumumab and AMG 479 | Completed | USA | POL | ESP | 0 |
NCT01336634 | Phase II | Dabrafenib Dabrafenib + Trametinib | Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | Completed | USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU | 3 |
NCT01336842 | Phase I | Cisplatin Panobinostat Pemetrexed Disodium | Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | Completed | USA | 0 |
NCT01344824 | Phase II | Bevacizumab Erlotinib Carboplatin Pemetrexed Disodium | Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers | Completed | USA | 0 |
NCT01351415 | Phase III | Bevacizumab | A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer | Completed | USA | SVK | NLD | LBN | ITA | GRC | FRA | ESP | DNK | DEU | BRA | BEL | AUT | ARG | 4 |
NCT01383148 | Phase Ib/II | MVA-MUC1-IL2 vaccine | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer | Terminated | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | BEL | 0 |
NCT01386385 | Phase Ib/II | Carboplatin + Paclitaxel Carboplatin + Etoposide + Veliparib | Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01391143 | Phase I | MGA271 | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
NCT01391533 | Phase I | SAR125844 | Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors | Completed | USA | ITA | FRA | ESP | 0 |
NCT01449461 | Phase Ib/II | Brigatinib | A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 | Completed | 0 | |
NCT01454102 | Phase I | Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | Completed | USA | CAN | 0 |
NCT01455389 | Phase Ib/II | Quaratusugene Ozeplasmid Erlotinib Diphenhydramine Dexamethasone | FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer | Terminated | USA | 0 |
NCT01456325 | Phase III | Erlotinib Onartuzumab | A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) | Completed | USA | POL | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 10 |
NCT01465802 | Phase II | Dacomitinib Alclometasone Doxycycline | Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO | Completed | USA | 1 |
NCT01487265 | Phase II | Buparlisib + Erlotinib | Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib | Completed | USA | 0 |
NCT01493843 | Phase II | Carboplatin Pictilisib Bevacizumab | Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | Completed | USA | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 3 |
NCT01514864 | Phase II | Dasatinib | Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | Terminated | USA | POL | GBR | DEU | CAN | BRA | 1 |
NCT01526928 | Phase Ib/II | Rociletinib | Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | Terminated | USA | POL | FRA | AUS | 0 |
NCT01532089 | Phase II | Bevacizumab Bevacizumab + Erlotinib | Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | Completed | USA | 0 |
NCT01537744 | Phase I | Azacitidine + Romidepsin | A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01545947 | Phase I | Azacitidine + Onatasertib Erlotinib + Onatasertib | Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer | Completed | USA | ESP | 0 |
NCT01553942 | Phase II | Afatinib Cisplatin Pemetrexed Disodium | Afatinib With CT and RT for EGFR-Mutant NSCLC | Active, not recruiting | USA | 0 |
NCT01573702 | Phase II | Erlotinib | Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) | Completed | USA | 0 |
NCT01574729 | Phase II | rAD-p53 | Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma | Unknown status | 1 | |
NCT01578551 | Phase II | Metformin Carboplatin + Paclitaxel Bevacizumab | A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. | Terminated | USA | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | NLD | GBR | FRA | ESP | AUS | 1 |
NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | DNK | CAN | 0 |
NCT01620190 | Phase II | Nab-paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01621542 | Phase I | WT2725 | Clinical Study of WT2725 in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT01628471 | Phase Ib/II | Decitabine + Genistein | MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer | Completed | CAN | 0 |
NCT01630733 | Phase III | Docetaxel Custirsen + Docetaxel | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer | Unknown status | USA | POL | NZL | ITA | ISR | HUN | ESP | DEU | AUS | 6 |
NCT01639508 | Phase II | Cabozantinib | Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity | Recruiting | USA | 0 |
NCT01642251 | Phase Ib/II | Cisplatin + Etoposide Veliparib | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Terminated | USA | 0 |
NCT01646125 | Phase II | Docetaxel Luminespib Pemetrexed Disodium | An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | Terminated | USA | POL | NOR | NLD | ITA | GBR | FRA | ESP | 4 |
NCT01647711 | Phase I | Afatinib | A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations | Completed | USA | 0 |
NCT01649284 | Phase I | Afatinib | Afatinib Expanded Access Program | Approved for marketing | USA | 0 |
NCT01649947 | Phase II | Bevacizumab + Carboplatin + Hydroxychloroquine + Paclitaxel Carboplatin + Hydroxychloroquine + Paclitaxel | Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II | Completed | USA | 0 |
NCT01653470 | Phase I | Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT01664754 | Phase I | Pemetrexed Disodium Carboplatin Exemestane | Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01676714 | Phase II | Dovitinib | Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer | Completed | USA | 0 |
NCT01700400 | Phase I | Carboplatin Everolimus Bevacizumab Pemetrexed Disodium | Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer | Completed | USA | 0 |
NCT01708993 | Phase II | Docetaxel Pemetrexed Disodium Pelareorep + Pemetrexed Disodium Docetaxel + Pelareorep | Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy | Completed | CAN | 0 |
NCT01712217 | Phase Ib/II | Crizotinib Onalespib | A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib | Completed | USA | FRA | ESP | CAN | 1 |
NCT01717482 | Phase II | Metformin | Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT01720836 | Phase Ib/II | MUC1 peptide-Poly-ICLC vaccine | Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT01723800 | Phase I | Buparlisib + Carboplatin + Pemetrexed Disodium | PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01725165 | Phase II | Oligometastatic Disease | Completed | USA | CAN | 0 | |
NCT01730118 | Phase I | HER2 Vaccine | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | Completed | USA | 0 |
NCT01746251 | Phase II | Afatinib | Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation | Unknown status | USA | 0 |
NCT01750281 | Phase II | Docetaxel Docetaxel + Selumetinib | Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. | Completed | USA | POL | NLD | HUN | FRA | DEU | BRA | BGR | 0 |
NCT01752400 | Phase II | Luminespib | AUY922 for Advanced ALK-positive NSCLC | Completed | USA | 0 |
NCT01769391 | Phase II | Necitumumab Carboplatin + Paclitaxel | A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer | Completed | USA | POL | DEU | 3 |
NCT01772797 | Phase I | Ceritinib Luminespib | Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer | Completed | USA | ITA | ESP | AUS | 1 |
NCT01783197 | Phase I | Selumetinib | Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC | Completed | CAN | 0 |
NCT01784640 | Phase I | Luminespib + Pemetrexed Disodium | Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01788566 | Phase II | Cisplatin + Gemcitabine + Necitumumab | A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer | Completed | USA | NLD | FRA | ESP | CAN | 2 |
NCT01798485 | Phase III | Ganetespib Docetaxel | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC | Terminated | USA | SVN | ROU | POL | NLD | ITA | HUN | HRV | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 5 |
NCT01801111 | Phase II | Erlotinib Alectinib | A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment | Completed | USA | SWE | NLD | LUX | ITA | GBR | FRA | ESP | DNK | DEU | BEL | AUS | 4 |
NCT01802632 | Phase Ib/II | Osimertinib | AZD9291 First Time In Patients Ascending Dose Study (AURA) | Completed | USA | ITA | GBR | FRA | ESP | DEU | AUS | 3 |
NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed | USA | 0 |
NCT01813734 | Phase II | Ponatinib | Ponatinib in Advanced NSCLC w/ RET Translocations | Completed | USA | 0 |
NCT01820754 | Phase II | Cisplatin Ipilimumab Carboplatin Paclitaxel | Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT01822496 | Phase II | Carboplatin + Cisplatin + Erlotinib + Etoposide + Paclitaxel | Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT01828112 | Phase III | Docetaxel Pemetrexed Disodium Ceritinib | LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | Completed | USA | TUR | NLD | LBN | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CHE | CAN | BEL | 6 |
NCT01829217 | Phase II | Sunitinib | Sunitinib in Never-Smokers With Lung Adenocarcinoma | Completed | USA | 0 |
NCT01831089 | Phase I | Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Completed | USA | ESP | CHE | 0 |
NCT01833143 | Phase II | Bortezomib | Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D | Completed | USA | 0 |
NCT01837329 | Phase I | Tetrathiomolybdate | Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01839955 | Phase Ib/II | Erlotinib + Quinacrine | Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01848756 | Phase Ib/II | SNX-5422 | Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers | Terminated | USA | 0 |
NCT01851369 | Phase Ib/II | Temozolomide + TRC102 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01854034 | Phase II | Luminespib | Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR | Completed | USA | 0 |
NCT01857271 | Phase II | Erlotinib | Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT01858389 | Phase II | Dacomitinib | A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer | Completed | USA | 1 |
NCT01859026 | Phase I | Binimetinib + Erlotinib | A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | Completed | USA | 0 |
NCT01866410 | Phase II | Cabozantinib + Erlotinib | Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01868022 | Phase I | Docetaxel Cisplatin + Pemetrexed Disodium GSK3052230 Carboplatin + Paclitaxel | Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | Completed | USA | NLD | GBR | ESP | DNK | BEL | 1 |
NCT01871805 | Phase Ib/II | Alectinib | A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer | Completed | USA | CAN | 0 |
NCT01884285 | Phase I | AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib | AZD8186 First Time In Patient Ascending Dose Study | Completed | USA | GBR | ESP | CAN | 0 |
NCT01887886 | Phase III | Erlotinib + Onartuzumab | A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation | Completed | USA | FRA | ESP | DEU | 4 |
NCT01892046 | Phase I | Carboplatin SNX-5422 Paclitaxel | Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors | Completed | USA | 0 |
NCT01900652 | Phase II | Emibetuzumab + Erlotinib Emibetuzumab | A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants | Completed | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | BEL | 1 |
NCT01903993 | Phase II | Atezolizumab | A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" | Completed | USA | TUR | SWE | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 2 |
NCT01911325 | Phase Ib/II | Buparlisib Docetaxel | Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients | Terminated | USA | SWE | ITA | FRA | ESP | DEU | BEL | 1 |
NCT01911507 | Phase I | Capmatinib + Erlotinib | INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01912625 | Phase I | Carboplatin + Paclitaxel + Trametinib | Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT01920061 | Phase I | Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | Completed | USA | ITA | GBR | ESP | CAN | 0 |
NCT01928160 | Phase II | Erlotinib + Pemetrexed Disodium Pemetrexed Disodium Carboplatin Carboplatin + Erlotinib Cisplatin Cisplatin + Erlotinib | Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib | Withdrawn | 0 | |
NCT01928576 | Phase II | Nivolumab Entinostat Azacitidine | Phase II Anti-PD1 Epigenetic Priming Study in NSCLC. | Completed | USA | 0 |
NCT01933932 | Phase III | Docetaxel + Selumetinib | Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 6 |
NCT01935947 | Phase II | Gemcitabine Azacitidine + Entinostat Docetaxel + Irinotecan + Pemetrexed Disodium | Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT01946789 | Phase I | Nogapendekin alfa inbakicept | A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01947608 | Phase I | Ceritinib | Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC | No longer available | USA | ARG | 8 |
NCT01951690 | Phase II | Defactinib | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01957007 | Phase I | Docetaxel + Vantictumab | A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC | Completed | USA | 0 |
NCT01966003 | Phase III | Bevacizumab Bevacizumab-awwb Carboplatin + Paclitaxel | Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer | Completed | USA | BGR | AUS | 0 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | NLD | AUS | 0 |
NCT01967095 | Phase I | Erlotinib | Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer | Completed | USA | 0 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Active, not recruiting | USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | AUT | AUS | 1 |
NCT01970865 | Phase II | Lorlatinib Crizotinib | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | Completed | USA | ITA | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 5 |
NCT01974258 | Phase I | Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib | Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | Withdrawn | USA | 0 |
NCT01976741 | Phase I | Rogaratinib | Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor | Completed | USA | FRA | ESP | DEU | CHE | 2 |
NCT01988896 | Phase I | Atezolizumab + Cobimetinib | A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | DEU | CAN | AUS | 2 |
NCT01993810 | Phase III | Carboplatin + Pemetrexed Disodium Durvalumab Cisplatin + Etoposide Carboplatin + Paclitaxel | Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer | Active, not recruiting | USA | 0 |
NCT01998126 | Phase I | Erlotinib + Ipilimumab Crizotinib + Ipilimumab | Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts | Completed | USA | 0 |
NCT01999738 | Phase I | EC1456 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01999985 | Phase I | Afatinib + Dasatinib | Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02000947 | Phase Ib/II | Durvalumab + Tremelimumab | A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer | Completed | USA | ITA | GBR | FRA | ESP | BEL | AUS | 2 |
NCT02004106 | Phase I | Cergutuzumab amunaleukin | A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors | Completed | USA | NLD | GBR | FRA | FIN | ESP | DNK | CHE | 0 |
NCT02008227 | Phase III | Docetaxel Atezolizumab | A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK | Completed | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | AUT | ARG | 11 |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02013219 | Phase I | Alectinib + Atezolizumab Atezolizumab + Erlotinib | A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer | Completed | USA | GBR | FRA | ESP | 2 |
NCT02014337 | Phase I | Eribulin + Mifepristone | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Completed | USA | 0 |
NCT02014909 | Phase I | CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Completed | USA | 0 |
NCT02019979 | Phase II | Metformin | Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO) | Terminated | USA | 0 |
NCT02022982 | Phase Ib/II | Palbociclib + PD-0325901 | PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors | Completed | USA | 0 |
NCT02031458 | Phase II | Atezolizumab | A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH | Completed | USA | TUR | SVN | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BGR | BEL | AUS | 5 |
NCT02038699 | Phase Ib/II | ONC201 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Withdrawn | USA | 0 |
NCT02039674 | Phase Ib/II | Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pemetrexed Disodium Ipilimumab + Pembrolizumab Erlotinib + Pembrolizumab Gefitinib + Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021) | Completed | 0 | |
NCT02041533 | Phase III | Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | Completed | USA | TUR | SWE | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
NCT02043665 | Phase I | Coxsackievirus A21 | Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) | Completed | USA | GBR | AUS | 0 |
NCT02044601 | Phase Ib/II | Carboplatin + Onartuzumab + Paclitaxel Carboplatin + Erlotinib + Onartuzumab + Paclitaxel | Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) | Withdrawn | USA | 0 |
NCT02045446 | Phase II | Bevacizumab + Erlotinib Docetaxel + Gemcitabine | Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02047344 | Phase II | Antroquinonol | Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC | Completed | USA | 1 |
NCT02066636 | Phase III | Nivolumab | A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153) | Completed | USA | CAN | 0 |
NCT02071862 | Phase I | Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Completed | USA | 0 |
NCT02075840 | Phase III | Alectinib Crizotinib | A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | BRA | AUS | 16 |
NCT02079636 | Phase I | LY3023414 Abemaciclib Gemcitabine Pemetrexed Disodium Ramucirumab | A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) | Completed | USA | ESP | 0 |
NCT02080078 | Phase I | Erlotinib + Theophylline | A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline | Terminated | CAN | 0 |
NCT02085070 | Phase II | Pembrolizumab | MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | Completed | USA | 0 |
NCT02087176 | Phase II | Adavosertib Pegfilgrastim | A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer | Terminated | USA | 0 |
NCT02087241 | Phase II | Adavosertib Carboplatin + Pemetrexed Disodium | Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer | Terminated | USA | 0 |
NCT02087423 | Phase II | Durvalumab | A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC) | Active, not recruiting | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | 6 |
NCT02088112 | Phase I | Durvalumab + Gefitinib | MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). | Completed | USA | 2 |
NCT02091999 | Phase I | Enfortumab vedotin-ejfv | A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | Completed | USA | CAN | 0 |
NCT02094573 | Phase II | Brigatinib | A Phase 2, Multicenter, Randomized Study of AP26113 | Completed | 0 | |
NCT02106546 | Phase III | Veliparib Carboplatin + Paclitaxel | Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | Completed | USA | TUR | SWE | SVK | POL | NZL | NOR | NLD | LVA | LTU | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | EST | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUT | AUS | 9 |
NCT02108964 | Phase Ib/II | Nazartinib | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | Completed | USA | NLD | ESP | DEU | CAN | 4 |
NCT02109016 | Phase II | Lucitanib | A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer | Terminated | USA | ITA | FRA | ESP | DEU | 0 |
NCT02113813 | Phase I | Naquotinib | A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | Completed | USA | 0 |
NCT02115464 | Phase II | Metformin | Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy | Terminated | CAN | 0 |
NCT02117024 | Phase II | Cyclophosphamide + HS-110 Pemetrexed Disodium Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02119650 | Phase II | Cisplatin + Pemetrexed Disodium + Ruxolitinib Cisplatin + Pemetrexed Disodium | Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02122809 | Phase I | Chiauranib | Phase I Study of Chiauranib in Patients With Advanced Solid Tumors | Completed | 1 | |
NCT02122861 | Phase I | ID-LV305 | A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | Completed | USA | 0 |
NCT02125461 | Phase III | Durvalumab | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC) | Completed | USA | TUR | SVK | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 10 |
NCT02132598 | Phase II | Cabozantinib | Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | Terminated | USA | 0 |
NCT02133196 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine | T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT02134015 | Phase III | Erlotinib Erlotinib + Patritumab | Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) | Terminated | USA | POL | ITA | HUN | GBR | ESP | DEU | CZE | CAN | BEL | 0 |
NCT02134886 | Phase I | Erlotinib | Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection | Terminated | USA | 0 |
NCT02134912 | Phase II | Crizotinib + Pemetrexed Disodium Pemetrexed Disodium | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib | Terminated | USA | 0 |
NCT02142738 | Phase III | Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | Completed | 0 | |
NCT02143466 | Phase I | Osimertinib + Savolitinib Osimertinib + Selumetinib Durvalumab + Osimertinib | AZD9291 in Combination With Ascending Doses of Novel Therapeutics | Active, not recruiting | USA | POL | CAN | 5 |
NCT02147990 | Phase II | Rociletinib | TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | NLD | GBR | FRA | ESP | DEU | CHE | CAN | AUS | 3 |
NCT02151981 | Phase III | Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Osimertinib | AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3) | Completed | USA | SWE | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | AUS | 7 |
NCT02152631 | Phase III | Erlotinib Abemaciclib | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) | Active, not recruiting | USA | TUR | ROU | POL | ITA | ISR | GRC | FRA | ESP | DEU | CAN | BRA | AUT | ARG | 7 |
NCT02157792 | Phase I | Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine | M6620 First in Human Study | Completed | USA | GBR | 0 |
NCT02157883 | Phase I | Osimertinib Itraconazole + Osimertinib | Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) | Completed | USA | NLD | GBR | BEL | 2 |
NCT02163733 | Phase I | Osimertinib | Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer | Completed | GBR | FRA | ESP | 1 |
NCT02168777 | Phase Ib/II | Refametinib + Regorafenib Refametinib | Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer | Terminated | USA | 0 |
NCT02174172 | Phase I | Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab | A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | NLD | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02179671 | Phase II | Docetaxel + Selumetinib Gefitinib Durvalumab Osimertinib Tremelimumab | Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | Completed | USA | 0 |
NCT02183883 | Phase II | Afatinib | Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (DARWIN1) | Completed | GBR | 0 |
NCT02186301 | Phase II | Rociletinib Erlotinib | TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy | Terminated | USA | ITA | ESP | DEU | 3 |
NCT02186847 | Phase II | Metformin Carboplatin + Paclitaxel | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | Active, not recruiting | USA | ISR | CAN | 0 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Terminated | USA | FRA | ESP | CAN | 1 |
NCT02192541 | Phase I | Aflibercept + Ganetespib | Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas | Terminated | USA | 0 |
NCT02193152 | Phase I | Pazopanib | Pazopanib in Molecularly Selected Patients With Advanced NSCLC | Terminated | USA | 0 |
NCT02193282 | Phase III | Erlotinib | Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) | Active, not recruiting | USA | 1 |
NCT02194738 | Phase I | Nivolumab Crizotinib Erlotinib | Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | Recruiting | USA | 2 |
NCT02197234 | Phase I | Osimertinib + Simvastatin Simvastatin Osimertinib | Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC | Completed | USA | FRA | ESP | BEL | 1 |
NCT02197247 | Phase I | Osimertinib + Rifampin Osimertinib | Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC | Completed | USA | NLD | GBR | ESP | 2 |
NCT02201992 | Phase III | Crizotinib | Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) | Recruiting | USA | 2 |
NCT02206763 | Phase I | Erlotinib + Momelotinib | Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT02220894 | Phase III | Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | Completed | 0 | |
NCT02221739 | Phase II | Ipilimumab | Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02222922 | Phase I | Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin | A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | Completed | USA | ESP | 0 |
NCT02225405 | Phase I | Cisplatin + Docetaxel + Nintedanib | Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC) | Completed | USA | 0 |
NCT02228369 | Phase I | Osimertinib AZD3759 | Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM) | Completed | USA | AUS | 2 |
NCT02250326 | Phase II | Azacitidine + Nab-paclitaxel Nab-paclitaxel | Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | 0 |
NCT02257619 | Phase II | Docetaxel Itacitinib | Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02258607 | Phase I | Momelotinib Momelotinib + Trametinib | Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase | Terminated | USA | 0 |
NCT02259114 | Phase I | Birabresib | A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors | Completed | 0 | |
NCT02259582 | Phase II | Carboplatin + Pemetrexed Disodium Demcizumab | A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer | Completed | USA | ITA | ESP | BEL | AUS | 0 |
NCT02259621 | Phase II | Nivolumab | Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC | Active, not recruiting | USA | CAN | 0 |
NCT02264678 | Phase Ib/II | Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | HUN | GBR | FRA | ESP | CAN | BEL | AUS | 1 |
NCT02264990 | Phase III | Pemetrexed Disodium Carboplatin Paclitaxel Veliparib Cisplatin | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers | Completed | USA | TUR | NZL | NLD | ISR | HUN | GBR | FIN | ESP | DNK | DEU | CZE | CAN | AUS | ARG | 5 |
NCT02271139 | Phase III | Alectinib | Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib | No longer available | USA | 0 |
NCT02271906 | Phase II | Afatinib | The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting | Terminated | USA | 0 |
NCT02272413 | Phase III | Carboplatin + Paclitaxel Bevacizumab | Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer | Completed | USA | TUR | ROU | POL | ITA | HUN | HRV | GRC | GBR | ESP | DEU | BRA | BGR | ARG | 14 |
NCT02273375 | Phase III | Durvalumab | Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC | Active, not recruiting | USA | ROU | POL | NZL | NLD | ITA | HUN | FRA | ESP | CAN | BRA | BGR | AUS | 6 |
NCT02277457 | Phase I | Crizotinib Erlotinib | Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations | Withdrawn | USA | 0 |
NCT02279433 | Phase I | Taletrectinib | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | Completed | USA | 0 |
NCT02281409 | Phase Ib/II | Mogamulizumab | Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02283320 | Phase II | Docetaxel | A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer | Completed | USA | 1 |
NCT02289833 | Phase II | Ado-trastuzumab emtansine | A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Completed | USA | POL | ITA | ESP | DEU | CHE | 1 |
NCT02292550 | Phase Ib/II | Ceritinib + Ribociclib | Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. | Completed | USA | ITA | FRA | ESP | 2 |
NCT02296125 | Phase III | Erlotinib Osimertinib Gefitinib | AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA) | Active, not recruiting | USA | TUR | SWE | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUS | 11 |
NCT02298153 | Phase I | Atezolizumab + Epacadostat | A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02299141 | Phase I | Nintedanib | Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02299505 | Phase I | Ceritinib | Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | Completed | USA | TUR | POL | NLD | LBN | ITA | GRC | GBR | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | 7 |
NCT02303990 | Phase I | Pembrolizumab | RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers | Completed | USA | 0 |
NCT02308020 | Phase II | Abemaciclib | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | Completed | USA | ITA | ISR | FRA | ESP | CAN | BEL | AUT | AUS | 0 |
NCT02309177 | Phase I | Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab | Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer | Completed | USA | 0 |
NCT02309892 | Phase I | Carboplatin + L-DOS47 + Pemetrexed Disodium | A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC | Terminated | USA | 0 |
NCT02310464 | Phase I | OBI-821 + OBI-833 | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects | Completed | 1 | |
NCT02314364 | Phase II | A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC | Completed | USA | 0 | |
NCT02314481 | Phase II | Vemurafenib Atezolizumab Alectinib Ado-trastuzumab emtansine | Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII) | Active, not recruiting | GBR | 0 |
NCT02315066 | Phase I | PF-04518600 PF-04518600 + Utomilumab | Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | Completed | USA | NLD | FRA | 1 |
NCT02316002 | Phase II | Pembrolizumab | Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02317016 | Phase I | Osimertinib Rosuvastatin | Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer | Completed | USA | GBR | FRA | ESP | 0 |
NCT02318368 | Phase II | Erlotinib Erlotinib + Ficlatuzumab | A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label | Terminated | USA | ITA | AUS | 4 |
NCT02318771 | Phase I | Pembrolizumab | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02321293 | Phase I | Erlotinib + Gefitinib | A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC | Unknown status | CAN | 0 |
NCT02321501 | Phase I | Ceritinib + Everolimus | Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02321540 | Phase Ib/II | Ibrutinib | A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02322281 | Phase III | Pemetrexed Disodium Gemcitabine Paclitaxel Docetaxel Rociletinib | TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | Terminated | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 2 |
NCT02323126 | Phase II | Nazartinib + Nivolumab Capmatinib + Nivolumab | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | Terminated | USA | ITA | FRA | ESP | DEU | CHE | AUS | 1 |
NCT02327078 | Phase Ib/II | Epacadostat + Nivolumab | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | Completed | USA | GBR | 0 |
NCT02335918 | Phase Ib/II | Nivolumab + Varlilumab | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT02335944 | Phase Ib/II | Capmatinib + Nazartinib | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | Terminated | USA | NOR | ITA | FRA | ESP | DEU | CAN | AUS | 3 |
NCT02336451 | Phase II | Ceritinib | A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges | Completed | USA | TUR | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 5 |
NCT02337530 | Phase II | Selumetinib Cisplatin + Pemetrexed Disodium | Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer | Completed | CAN | 0 |
NCT02342353 | Phase Ib/II | Erlotinib + Pacritinib | Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) | Terminated | USA | 0 |
NCT02343952 | Phase II | Pembrolizumab | Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | Completed | USA | 0 |
NCT02346955 | Phase I | CM-24 CM-24 + Pembrolizumab | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | Terminated | USA | ISR | 0 |
NCT02349633 | Phase II | Avelumab + Mavelertinib Mavelertinib + Palbociclib Mavelertinib | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | Terminated | USA | AUS | 2 |
NCT02350764 | Phase II | Ipilimumab + Nivolumab | Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs | Completed | USA | 0 |
NCT02352948 | Phase III | Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) | Completed | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BGR | BEL | AUS | 9 |
NCT02355431 | Phase II | Erlotinib Itacitinib | INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | Withdrawn | USA | 0 |
NCT02357836 | Phase I | Itraconazole | Neoadjuvant Itraconazole in Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02364609 | Phase I | Afatinib + Pembrolizumab | Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib | Completed | USA | 0 |
NCT02364999 | Phase III | Bevacizumab + Carboplatin + Paclitaxel | A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC | Completed | USA | TUR | ROU | POL | NLD | ITA | HUN | HRV | GRC | FRA | ESP | DEU | CZE | BRA | BGR | AUS | 11 |
NCT02365662 | Phase I | ABBV-221 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | Terminated | USA | ESP | 0 |
NCT02366143 | Phase III | Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Nab-paclitaxel Atezolizumab + Carboplatin + Paclitaxel | TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer | Completed | USA | SVK | NLD | LVA | LTU | ITA | FRA | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 9 |
NCT02367781 | Phase III | Atezolizumab Carboplatin + Nab-paclitaxel | A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer | Completed | USA | ITA | ISR | FRA | ESP | DEU | CAN | BEL | 0 |
NCT02367794 | Phase III | Carboplatin Nab-paclitaxel Paclitaxel Atezolizumab | A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | SVK | NLD | LVA | LTU | ITA | ISR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 9 |
NCT02381314 | Phase I | Ipilimumab + MGA271 | Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer | Completed | USA | 0 |
NCT02382406 | Phase Ib/II | Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | Terminated | USA | 0 |
NCT02387125 | Phase I | CMB305 | A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Terminated | USA | 0 |
NCT02387216 | Phase II | Seribantumab Pemetrexed Disodium Docetaxel | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC | Terminated | USA | HUN | FRA | ESP | DEU | CAN | 0 |
NCT02391480 | Phase I | Mivebresib | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | Completed | USA | 0 |
NCT02392507 | Phase II | Carboplatin + Nab-paclitaxel + Necitumumab | A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC | Completed | USA | 0 |
NCT02393625 | Phase I | Ceritinib + Nivolumab | Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer | Active, not recruiting | USA | ITA | ESP | CAN | BEL | AUS | 2 |
NCT02395172 | Phase III | Avelumab Docetaxel | Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) | Completed | USA | TUR | SVK | ROU | POL | ITA | ISR | HUN | HRV | GBR | FRA | ESP | DNK | CZE | CHE | BRA | BGR | BEL | AUS | ARG | 9 |
NCT02400814 | Phase I | Atezolizumab | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT02403193 | Phase Ib/II | Spartalizumab + Taminadenant Taminadenant | Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO) | Completed | USA | 0 |
NCT02403271 | Phase Ib/II | Durvalumab + Ibrutinib | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02404441 | Phase Ib/II | Spartalizumab | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | Completed | USA | TUR | POL | NOR | NLD | LBN | ITA | HUN | FRA | ESP | DEU | CAN | 2 |
NCT02407171 | Phase Ib/II | Pembrolizumab | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | Completed | USA | 0 |
NCT02409342 | Phase III | Atezolizumab Carboplatin Pemetrexed Disodium Cisplatin | A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | TUR | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | BRA | 7 |
NCT02409355 | Phase III | Carboplatin Cisplatin Gemcitabine Atezolizumab | A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer | Terminated | USA | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | 3 |
NCT02411448 | Phase III | Erlotinib Gefitinib + Ramucirumab Erlotinib + Ramucirumab Osimertinib + Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY) | Active, not recruiting | USA | TUR | ROU | ITA | GRC | GBR | FRA | ESP | DEU | CAN | 4 |
NCT02412371 | Phase II | Veliparib Carboplatin + Paclitaxel | A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02414139 | Phase II | Capmatinib | Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (Geometry Mono-1) | Completed | USA | SWE | NOR | NLD | LBN | ITA | ISR | GBR | FRA | ESP | DEU | BEL | AUT | ARG | 6 |
NCT02414269 | Phase I | Cyclophosphamide + iCasp9M28z T cells iCasp9M28z T cells | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | Active, not recruiting | USA | 0 |
NCT02422381 | Phase Ib/II | Gemcitabine Pembrolizumab | MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT02422589 | Phase I | Warfarin Midazolam Ceritinib | A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors | Completed | USA | ITA | ESP | DNK | 0 |
NCT02423343 | Phase Ib/II | Galunisertib Nivolumab | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma | Completed | USA | ESP | 0 |
NCT02424617 | Phase Ib/II | Bemcentinib + Erlotinib | A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02435121 | Phase II | SAR125844 | A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification | Completed | BEL | 0 |
NCT02437136 | Phase Ib/II | Entinostat + Pembrolizumab | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma | Completed | USA | 0 |
NCT02438722 | Phase II | Afatinib Afatinib + Cetuximab | S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02439450 | Phase I | HS-110 Nivolumab | A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02443324 | Phase I | Pembrolizumab + Ramucirumab | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium | Completed | USA | GBR | FRA | ESP | DEU | 1 |
NCT02444741 | Phase Ib/II | Pembrolizumab | MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT02448251 | Phase I | Abivertinib | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer | Terminated | USA | FRA | ESP | 0 |
NCT02448303 | Phase II | Acalabrutinib Pembrolizumab | Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02450539 | Phase II | Abemaciclib Docetaxel | A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer | Completed | USA | ROU | POL | ITA | HUN | FRA | ESP | DEU | AUS | 4 |
NCT02451852 | Phase I | Osimertinib | AZD9291 US Expanded Access Program | No longer available | USA | 0 |
NCT02451865 | Phase I | Binimetinib + Docetaxel | Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT02451930 | Phase I | Necitumumab Pembrolizumab | A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC | Completed | USA | FRA | ESP | 1 |
NCT02452424 | Phase Ib/II | Pembrolizumab + Pexidartinib | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Terminated | USA | 0 |
NCT02453282 | Phase III | Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) | Active, not recruiting | USA | NLD | ITA | HUN | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 6 |
NCT02454842 | Phase II | TH-4000 | Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC | Terminated | USA | AUS | 0 |
NCT02454933 | Phase III | Osimertinib Durvalumab | Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL) | Completed | CAN | 2 |
NCT02460224 | Phase Ib/II | Ieramilimab Spartalizumab | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT02460367 | Phase Ib/II | Docetaxel + Indoximod | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02463994 | Phase I | Atezolizumab | A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC | Completed | USA | 0 |
NCT02468661 | Phase I | Capmatinib Capmatinib + Erlotinib Erlotinib Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification | Terminated | USA | NLD | ITA | FRA | ESP | DEU | BEL | 3 |
NCT02469701 | Phase II | Nivolumab | BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease | Terminated | USA | 0 |
NCT02471846 | Phase I | Navoximod Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
NCT02474355 | Phase III | Osimertinib | Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC | Completed | SWE | ITA | IRL | GBR | ESP | DNK | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
NCT02475213 | Phase I | MGA271 + Pembrolizumab | Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer | Completed | USA | 0 |
NCT02475382 | Expanded access | Nivolumab | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169) | No longer available | CAN | BRA | 0 |
NCT02477826 | Phase III | Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | ROU | POL | NLD | LBN | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
NCT02485652 | Phase II | Olmutinib | Phase II Trial of HM61713 for the Treatment of >= 2nd Line T790M Mutation Positive Adenocarcinoma of the Lung | Terminated | USA | ITA | ESP | DEU | CAN | AUS | 4 |
NCT02486718 | Phase III | Atezolizumab | Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer | Active, not recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 8 |
NCT02487095 | Phase Ib/II | Berzosertib Topotecan | Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02489903 | Phase II | Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel | RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens | Completed | USA | 0 |
NCT02492867 | Phase 0 | Durvalumab Carboplatin + Paclitaxel | A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02495636 | Phase II | Atezolizumab + Rasdegafusp alfa | Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT02496663 | Phase I | Necitumumab + Osimertinib | Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor | Active, not recruiting | USA | 0 |
NCT02498613 | Phase II | Cediranib + Olaparib | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02500199 | Phase I | Pyrotinib | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | Unknown status | USA | 0 |
NCT02501096 | Phase Ib/II | Pembrolizumab Lenvatinib | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Completed | USA | NOR | ESP | 0 |
NCT02503722 | Phase I | Osimertinib + Sapanisertib | Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
NCT02504372 | Phase III | Pembrolizumab | Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) | Active, not recruiting | 0 | |
NCT02504489 | Phase III | Docetaxel Docetaxel + Plinabulin | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3) | Completed | USA | AUS | 1 |
NCT02509507 | Phase I | Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab | Completed | USA | POL | ESP | DEU | CHE | BEL | AUT | AUS | 1 |
NCT02511106 | Phase III | Osimertinib | AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | HUN | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 9 |
NCT02511184 | Phase I | Crizotinib Pembrolizumab | Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients | Terminated | USA | 0 |
NCT02514174 | FDA approved | Afatinib | Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older | Completed | USA | 0 |
NCT02516813 | Phase I | Peposertib | Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy | Completed | USA | SWE | NOR | NLD | DNK | DEU | CHE | BEL | 0 |
NCT02520778 | Phase I | Navitoclax + Osimertinib | Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02521051 | Phase Ib/II | Bevacizumab Alectinib | Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer | Unknown status | USA | 0 |
NCT02523469 | Phase Ib/II | Nivolumab + Nogapendekin alfa inbakicept | ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02525757 | Phase II | Atezolizumab Carboplatin + Paclitaxel | MPDL3280A With Chemoradiation for Lung Cancer | Active, not recruiting | USA | 0 |
NCT02526017 | Phase I | Cabiralizumab Nivolumab | Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers | Completed | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | FRA | CAN | 0 |
NCT02535338 | Phase Ib/II | Erlotinib + Onalespib | Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02537561 | Phase I | Talazoparib Cisplatin + Gemcitabine | Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors | Withdrawn | 0 | |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | FRA | 0 |
NCT02542293 | Phase III | Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab + Tremelimumab Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE) | Active, not recruiting | USA | TUR | SWE | ROU | POL | ISR | GRC | GBR | FIN | DNK | BRA | BGR | ARG | 16 |
NCT02543645 | Phase Ib/II | Atezolizumab + Varlilumab | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT02544633 | Phase II | Glesatinib | Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET | Completed | USA | POL | ITA | HUN | GBR | CAN | AUS | 2 |
NCT02546986 | Phase II | Azacitidine + Pembrolizumab Pembrolizumab | Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer | Active, not recruiting | USA | ITA | GRC | FRA | ESP | DEU | 0 |
NCT02547675 | Phase I | Rociletinib | Rociletinib (CO-1686) USA Expanded Access Program | No longer available | USA | 0 |
NCT02554812 | Phase Ib/II | Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Terminated | USA | POL | GBR | FRA | CAN | AUS | 2 |
NCT02563548 | Phase I | PEGPH20 + Pembrolizumab | Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab | Completed | USA | 0 |
NCT02568267 | Phase II | Entrectinib | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 6 |
NCT02572687 | Phase I | Durvalumab + Ramucirumab | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | Completed | USA | ITA | ISR | FRA | ESP | DEU | 2 |
NCT02573259 | Phase I | PF-06801591 | A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | Completed | USA | POL | BGR | 4 |
NCT02574078 | Phase Ib/II | Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Disodium Bevacizumab Carboplatin + Pemetrexed Disodium Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Disodium Gemcitabine | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) | Completed | USA | 0 |
NCT02575781 | Phase I | SAR428926 | A Study of SAR428926 in Patients With Advanced Solid Tumors | Completed | FRA | ESP | DNK | 0 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Active, not recruiting | USA | TUR | SWE | SVK | ITA | IRL | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT02576574 | Phase III | Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin | Avelumab in First-line NSCLC (JAVELIN Lung 100) | Completed | USA | TUR | SVK | ROU | POL | NZL | NLD | LTU | LBN | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | EST | ESP | DNK | DEU | CZE | CYP | CAN | BRA | BGR | BEL | AUS | 14 |
NCT02576665 | Phase I | Toca FC + Vocimagene amiretrorepvec | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) | Terminated | USA | 0 |
NCT02578680 | Phase III | Carboplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | Completed | 0 | |
NCT02580708 | Phase Ib/II | Trametinib Rociletinib | A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT02581787 | Phase Ib/II | Fresolimumab | SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02581943 | Phase II | Paclitaxel Pembrolizumab Carboplatin | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02584634 | Phase I | Crizotinib Avelumab Lorlatinib | Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | Terminated | USA | ESP | AUS | 2 |
NCT02588261 | Phase III | Naquotinib Gefitinib Erlotinib | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations | Terminated | USA | ROU | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 11 |
NCT02589522 | Phase I | Berzosertib | VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02591615 | Phase II | Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium | Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC | Completed | USA | 0 |
NCT02592577 | Phase I | MAGE A10c796T for Advanced NSCLC | Completed | USA | GBR | ESP | CAN | 0 | |
NCT02595866 | Phase I | Pembrolizumab | Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms | Completed | USA | 0 |
NCT02595944 | Phase III | Nivolumab | Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) | Active, not recruiting | USA | 0 |
NCT02599454 | Phase I | Atezolizumab | Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02605746 | Phase I | Ceritinib | Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis | Completed | USA | 0 |
NCT02608268 | Phase Ib/II | Spartalizumab Sabatolimab | Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Terminated | USA | NLD | ITA | CHE | CAN | 4 |
NCT02608385 | Phase I | Pembrolizumab | Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02609776 | Phase I | Amivantamab-vmjw Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Amivantamab-vmjw + Lazertinib | Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS) | Active, not recruiting | USA | GBR | FRA | ESP | CAN | AUS | 4 |
NCT02616393 | Phase II | Tesevatinib | Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases | Completed | USA | 0 |
NCT02621398 | Phase I | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02630186 | Phase Ib/II | Atezolizumab + Rociletinib | A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC | Terminated | USA | 0 |
NCT02635061 | Phase I | Citarinostat + Ipilimumab + Nivolumab | Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02637531 | Phase I | Pembrolizumab Eganelisib | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | Unknown status | USA | 0 |
NCT02638090 | Phase Ib/II | Pembrolizumab Vorinostat | Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT02639026 | Phase I | Durvalumab + Tremelimumab | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | Completed | USA | 0 |
NCT02639091 | Phase I | Anetumab ravtansine + Cisplatin + Pemetrexed Disodium | Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors | Completed | USA | ITA | 0 |
NCT02639234 | Phase II | FANG vaccine + Nivolumab | Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT02640508 | Phase II | Eribulin + Lenvatinib | Eribulin and Lenvatinib in Advanced Solid Tumors | Completed | USA | 0 |
NCT02642042 | Phase II | Docetaxel + Trametinib | Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02642939 | Phase II | Mifepristone | Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02648724 | Phase Ib/II | SYM015 | Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies | Completed | USA | ESP | DNK | 3 |
NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |
NCT02654587 | Phase III | OSE 2101 Pemetrexed Disodium Docetaxel | Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1) | Terminated | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | 0 |
NCT02658097 | Phase II | Pembrolizumab | A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC | Completed | USA | 0 |
NCT02659059 | Phase II | Ipilimumab + Nivolumab | Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568) | Completed | USA | CAN | 0 |
NCT02664181 | Phase II | Nivolumab Decitabine + Nivolumab + Tetrahydrouridine | Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE) | Completed | USA | 0 |
NCT02665416 | Phase I | RO5520985 + Selicrelumab Bevacizumab + Selicrelumab | Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors | Completed | USA | NLD | ITA | ESP | DNK | CAN | BEL | 0 |
NCT02666105 | Phase II | Exemestane | Exemestane in Post-Menopausal Women With NSCLC | Completed | USA | 0 |
NCT02669914 | Phase II | Durvalumab | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | Terminated | USA | 0 |
NCT02671955 | Phase I | Onvatilimab | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated | USA | 0 |
NCT02681549 | Phase II | Bevacizumab + Pembrolizumab | Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02684461 | Phase II | Pembrolizumab | Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel | Completed | USA | 0 |
NCT02695290 | Phase III | Afatinib | Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) | Terminated | USA | 0 |
NCT02696993 | Phase Ib/II | Nivolumab Ipilimumab + Nivolumab | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02697591 | Phase Ib/II | INCAGN01876 | An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02698176 | Phase I | Birabresib | A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) | Terminated | 0 | |
NCT02706392 | Phase I | Cyclophosphamide + Fludarabine + ROR1 CAR-T cells | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Terminated | USA | 0 |
NCT02706626 | Phase II | Brigatinib | Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors | Terminated | USA | 0 |
NCT02710396 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Genetic Predictors of Benefit to Pembrolizumab | Terminated | USA | 0 |
NCT02713529 | Phase Ib/II | AMG 820 + Pembrolizumab | Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | Completed | USA | ESP | DEU | CAN | BEL | AUS | 0 |
NCT02713828 | Phase Ib/II | Glembatumumab vedotin | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung | Terminated | USA | 0 |
NCT02713867 | Phase III | Nivolumab | A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384) | Completed | USA | ITA | FRA | ESP | DEU | CAN | AUT | AUS | 0 |
NCT02715284 | Phase I | Dostarlimab-gxly | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DNK | CZE | CAN | BRA | ARG | 2 |
NCT02716038 | Phase II | Atezolizumab + Carboplatin + Nab-paclitaxel | Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | Completed | USA | 0 |
NCT02716116 | Phase Ib/II | Mobocertinib | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | Active, not recruiting | USA | ITA | GBR | ESP | DEU | 5 |
NCT02718066 | Phase Ib/II | Chidamide + Nivolumab | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02723955 | Phase I | GSK3359609 GSK3359609 + Pembrolizumab | Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) | Completed | USA | NLD | ITA | FRA | ESP | CAN | AUS | 2 |
NCT02730247 | Phase II | Nab-paclitaxel + Ramucirumab | Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02733250 | Phase Ib/II | Nab-paclitaxel + Pembrolizumab | Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001) | Completed | CAN | 0 |
NCT02737501 | Phase III | Brigatinib Crizotinib | ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L) | Completed | USA | SWE | NOR | NLD | LUX | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | AUT | AUS | 4 |
NCT02740985 | Phase I | AZD4635 AZD4635 + Durvalumab | A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies | Completed | USA | 0 |
NCT02750215 | Phase II | Capmatinib | A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor | Completed | USA | 0 |
NCT02750514 | Phase II | Dasatinib + Nivolumab Nivolumab + Relatlimab Nivolumab Linrodostat + Nivolumab | An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung) | Terminated | USA | ITA | FRA | ESP | CHE | CAN | AUT | AUS | 0 |
NCT02767804 | Phase III | Crizotinib Ensartinib | eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 4 |
NCT02768558 | Phase III | Cisplatin + Etoposide Cisplatin + Etoposide + Nivolumab | Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC | Terminated | USA | 0 |
NCT02770014 | Phase II | Erlotinib | Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer | Terminated | USA | 0 |
NCT02775435 | Phase III | Carboplatin + Nab-paclitaxel Pembrolizumab Carboplatin + Paclitaxel | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | Completed | 0 | |
NCT02779751 | Phase II | Abemaciclib + Pembrolizumab | A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer | Active, not recruiting | USA | TUR | ITA | FRA | ESP | BEL | 1 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Completed | USA | NLD | FRA | CAN | 0 |
NCT02784158 | Phase I | Brigatinib | An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer | No longer available | USA | 0 |
NCT02789345 | Phase I | Osimertinib + Ramucirumab Necitumumab + Osimertinib | A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer | Completed | USA | FRA | ESP | 2 |
NCT02795156 | Phase II | Cabozantinib Afatinib Regorafenib | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | Completed | USA | 0 |
NCT02803203 | Phase Ib/II | Bevacizumab + Osimertinib | Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | Completed | USA | 0 |
NCT02805660 | Phase Ib/II | Durvalumab + Mocetinostat | Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC | Terminated | USA | 0 |
NCT02812667 | Phase I | Nivolumab + Plinabulin | Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT02817633 | Phase I | Cobolimab Cobolimab + Dostarlimab-gxly + TSR-033 Cisplatin + Cobolimab + Dostarlimab-gxly + Pemetrexed Disodium Cobolimab + Dostarlimab-gxly Cobolimab + Nivolumab Cobolimab + Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | Recruiting | USA | ESP | 2 |
NCT02818426 | Phase Ib/II | UCPVax | Universal Cancer Peptide-based Vaccination in Metastatic NSCLC (UCPVax) | Completed | FRA | 0 |
NCT02818920 | Phase II | Pembrolizumab | Neoadjuvant Pembrolizumab | Active, not recruiting | USA | 0 |
NCT02823990 | Phase II | MVA-MUC1-IL2 vaccine + Nivolumab | TG4010 and Nivolumab in Patients With Lung Cancer | Completed | USA | 0 |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |
NCT02826161 | Phase III | Napabucasin + Paclitaxel Paclitaxel | A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L) | Terminated | USA | 0 |
NCT02829099 | Phase I | JNJ-64457107 | A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors | Completed | ISR | ESP | 0 |
NCT02831491 | Phase II | Docetaxel + Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer | Withdrawn | 0 | |
NCT02831933 | Phase II | AdV-tk + Nivolumab | Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma (ENSIGN) | Terminated | USA | 0 |
NCT02834247 | Phase I | Mivavotinib + Nivolumab | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | Terminated | USA | ITA | GBR | ESP | 0 |
NCT02835833 | Phase I | Bevacizumab + Nintedanib | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | Completed | USA | 0 |
NCT02840994 | Phase Ib/II | CV301 + Nivolumab Nivolumab | A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02846792 | Phase Ib/II | Nivolumab + Plinabulin | Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT02848651 | Phase II | Atezolizumab | A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST] | Completed | USA | 0 |
NCT02855125 | Phase II | Tegafur-gimeracil-oteracil Potassium TAS-114 + Tegafur-gimeracil-oteracil Potassium | A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 | Completed | USA | POL | ITA | FRA | ESP | 1 |
NCT02857270 | Phase I | LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Completed | USA | FRA | AUS | 1 |
NCT02858869 | Phase 0 | Pembrolizumab | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | Completed | USA | 0 |
NCT02860780 | Phase I | Prexasertib + Ralimetinib | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | Completed | USA | DEU | 0 |
NCT02864251 | Phase III | Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Pemetrexed Disodium | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722) | Completed | USA | FRA | ESP | CAN | 6 |
NCT02869789 | Phase III | Ipilimumab + Nivolumab | A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | Completed | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | ARG | 3 |
NCT02879617 | Phase II | Durvalumab | A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients | Completed | USA | 0 |
NCT02879760 | Phase Ib/II | Ad-MAGEA3 + MG1-MAGEA3 + Pembrolizumab | Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | Completed | CAN | 0 |
NCT02879994 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02888743 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
NCT02890069 | Phase I | LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Completed | USA | NLD | GBR | ESP | DEU | 2 |
NCT02897375 | Phase I | Cisplatin + Palbociclib Carboplatin + Palbociclib | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | Completed | USA | 0 |
NCT02897765 | Phase I | Nivolumab NEO-PV-01 + Poly ICLC | A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | Completed | USA | 0 |
NCT02898116 | Phase Ib/II | Durvalumab + Ensartinib Ensartinib | A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02900664 | Phase I | Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) | Completed | USA | ITA | ISR | FRA | ESP | CAN | BEL | 2 |
NCT02904954 | Phase II | Durvalumab | Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02912949 | Phase Ib/II | Zenocutuzumab | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Recruiting | USA | SWE | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUT | 4 |
NCT02917993 | Phase Ib/II | Itacitinib + Osimertinib | An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | Active, not recruiting | USA | ESP | 2 |
NCT02919449 | Phase I | Atezolizumab + MV-NIS | Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02920450 | Phase Ib/II | Carboplatin + Gedatolisib + Paclitaxel | Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) | Terminated | USA | 0 |
NCT02920996 | Phase II | Merestinib | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | Terminated | USA | 0 |
NCT02922764 | Phase I | RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma | Active, not recruiting | USA | 0 |
NCT02922777 | Phase I | Bemcentinib + Docetaxel | Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. | Completed | USA | 0 |
NCT02923349 | Phase Ib/II | INCAGN01949 | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | CHE | 0 |
NCT02926768 | Phase Ib/II | CK-101 | Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors | Completed | USA | POL | NZL | AUS | 1 |
NCT02927301 | Phase II | Atezolizumab | A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02927340 | Phase II | Lorlatinib | A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions | Unknown status | USA | 0 |
NCT02941601 | Phase II | Carboplatin + Gemcitabine + Necitumumab | A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | Withdrawn | USA | ROU | ITA | GBR | DEU | BEL | 1 |
NCT02942095 | Phase I | Erlotinib + Ixazomib | Study of Ixazomib and Erlotinib in Solid Tumors | Completed | USA | 0 |
NCT02944396 | Phase II | Carboplatin + Paclitaxel + Pemetrexed Disodium + Veliparib Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Veliparib | Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Completed | USA | ITA | DEU | CHE | CAN | AUT | 3 |
NCT02947386 | Phase Ib/II | Nimotuzumab + Nivolumab | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02949843 | Phase II | Nivolumab + Pembrolizumab | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | Terminated | USA | 0 |
NCT02950038 | Phase II | Ibrutinib + Nivolumab | Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) | Withdrawn | 0 | |
NCT02952248 | Phase I | Ezabenlimab | A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours | Completed | USA | GBR | CAN | 0 |
NCT02952729 | Phase I | XMT-1522 | Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 | Completed | USA | 0 |
NCT02952989 | Phase I | SGN-2FF | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02954523 | Phase Ib/II | Dasatinib + Osimertinib | Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | Terminated | USA | 0 |
NCT02954991 | Phase II | Nivolumab + Sitravatinib Mocetinostat + Nivolumab Glesatinib + Nivolumab | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02955290 | Phase Ib/II | CIMAvax-EGF + Nivolumab | CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT02955758 | Phase II | Pembrolizumab | Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02959437 | Phase Ib/II | Azacitidine + Epacadostat + Pembrolizumab | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | Terminated | USA | GBR | ESP | 0 |
NCT02963610 | Phase Ib/II | Lenalidomide + Pembrolizumab | Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT02965885 | Phase I | Pimitespib | A Study of TAS-116 in Patients With Solid Tumors | Completed | USA | ITA | GBR | 0 |
NCT02967133 | Phase II | Nab-paclitaxel + Nivolumab Nivolumab | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT02971501 | Phase II | Osimertinib Bevacizumab + Osimertinib | Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases | Active, not recruiting | USA | 0 |
NCT02974725 | Phase I | LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | Terminated | USA | SWE | POL | ITA | ISR | FRA | ESP | DEU | BEL | AUS | 1 |
NCT02978404 | Phase II | Nivolumab | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | Completed | CAN | 0 |
NCT02981108 | Phase Ib/II | Aumolertinib | A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC | Unknown status | USA | 0 |
NCT02983045 | Phase Ib/II | Nivolumab + NKTR-214 | A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) | Completed | USA | POL | ITA | GBR | FRA | ESP | CAN | BEL | 0 |
NCT02983578 | Phase II | Danvatirsen + Durvalumab | AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02987998 | Phase I | Cisplatin + Etoposide + Pembrolizumab | Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC | Terminated | USA | 0 |
NCT02991651 | Phase I | Erlotinib + IRX4204 | Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC | Suspended | USA | 0 |
NCT02992912 | Phase II | Atezolizumab | Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) | Active, not recruiting | FRA | 0 |
NCT02994576 | Phase II | Atezolizumab | Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer (PRINCEPS) | Completed | FRA | 0 |
NCT02998528 | Phase III | Ipilimumab + Nivolumab Carboplatin + Cisplatin + Docetaxel + Gemcitabine + Pemetrexed Disodium + Vinorelbine | A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816) | Active, not recruiting | USA | TUR | ROU | ITA | HUN | GRC | FRA | ESP | CAN | BRA | ARG | 4 |
NCT02998567 | Phase I | Guadecitabine + Pembrolizumab Decitabine and Cedazuridine + Pembrolizumab | Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (HyPeR) | Recruiting | GBR | 0 |
NCT03001882 | Phase II | Ipilimumab + Nivolumab | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | ROU | NLD | ITA | FRA | ESP | DEU | BEL | 0 |
NCT03003468 | Phase Ib/II | Pembrolizumab + PGG beta-glucan | Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 | Completed | USA | 0 |
NCT03003962 | Phase III | Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + Paclitaxel | Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | Active, not recruiting | USA | TUR | POL | NLD | HUN | AUS | 6 |
NCT03004105 | Phase II | Durvalumab + Selumetinib | MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) | Withdrawn | 0 | |
NCT03004183 | Phase II | Pembrolizumab AdV-tk + Valacyclovir | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (STOMP) | Completed | USA | 0 |
NCT03014648 | Phase II | Atezolizumab | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT03023319 | Phase I | Bosutinib + Pemetrexed Disodium | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | Completed | USA | 0 |
NCT03023423 | Phase Ib/II | Atezolizumab + Daratumumab Atezolizumab | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX) | Completed | USA | POL | HUN | FRA | ESP | 0 |
NCT03023904 | Phase II | Nivolumab | Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads | Withdrawn | 0 | |
NCT03037385 | Phase Ib/II | Pralsetinib | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | 5 |
NCT03041181 | Phase II | Docetaxel + Nivolumab Docetaxel | Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab | Terminated | USA | 0 |
NCT03042013 | Phase II | Naquotinib | A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study | Withdrawn | 0 | |
NCT03048136 | Phase III | Ipilimumab + Nivolumab | A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955) | Withdrawn | USA | DEU | CAN | ARG | 1 |
NCT03048500 | Phase II | Metformin + Nivolumab | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | Unknown status | USA | 0 |
NCT03049618 | Phase II | Pembrolizumab + sEphB4-HSA | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | Active, not recruiting | USA | 0 |
NCT03050060 | Phase II | Nelfinavir + Nivolumab | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | Terminated | USA | 0 |
NCT03050554 | Phase Ib/II | Avelumab | Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT03052608 | Phase III | Lorlatinib Crizotinib | A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | Active, not recruiting | USA | TUR | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | ARG | 9 |
NCT03054038 | Phase I | Afatinib + Necitumumab | Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT03057106 | Phase II | Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium | Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | Active, not recruiting | CAN | AUS | 0 |
NCT03064854 | Phase I | Canakinumab + Cisplatin + Pemetrexed Disodium + Spartalizumab Canakinumab + Carboplatin + Spartalizumab Carboplatin + Paclitaxel + Spartalizumab Cisplatin + Pemetrexed Disodium + Spartalizumab Cisplatin + Gemcitabine + Spartalizumab | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | Terminated | USA | NLD | ITA | FRA | ESP | DEU | CZE | CAN | BEL | 3 |
NCT03066206 | Phase II | Poziotinib | Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | Active, not recruiting | USA | 0 |
NCT03071757 | Phase I | ABBV-368 ABBV-368 + Nivolumab | A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 3 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03082300 | Phase I | Naquotinib | A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations | Terminated | USA | 0 |
NCT03083808 | Phase II | Gemcitabine + Pembrolizumab Docetaxel + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium | Phase II Trial of Continuation Therapy in Advanced NSCLC | Completed | USA | 0 |
NCT03086733 | Phase II | Metformin | Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (Metcore) | Completed | CAN | 0 |
NCT03087448 | Phase Ib/II | Ceritinib + Trametinib | Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT03087760 | Phase II | Pembrolizumab | Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03088930 | Phase II | Crizotinib | Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT03090737 | Phase II | Nivolumab | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907) | Completed | USA | ROU | CAN | 2 |
NCT03093116 | Phase Ib/II | Repotrectinib | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | Recruiting | USA | POL | NLD | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 7 |
NCT03095612 | Phase Ib/II | Docetaxel + Selinexor | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT03098550 | Phase Ib/II | Daratumumab + Nivolumab | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread | Completed | USA | ITA | FRA | ESP | DEU | CHE | CAN | AUS | 1 |
NCT03099174 | Phase I | Abemaciclib + Xentuzumab Abemaciclib + Letrozole + Xentuzumab Abemaciclib + Anastrozole + Xentuzumab Abemaciclib + Fulvestrant + Xentuzumab | This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. | Completed | USA | FRA | FIN | ESP | DNK | 2 |
NCT03101839 | Phase I | AZD4785 | Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours | Completed | USA | GBR | 0 |
NCT03102242 | Phase II | Atezolizumab | Atezolizumab Immunotherapy in Patients With Advanced NSCLC | Completed | USA | 0 |
NCT03102606 | Phase II | Plinabulin Pegfilgrastim | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) | Completed | USA | 3 |
NCT03110978 | Phase II | Nivolumab | Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR | Active, not recruiting | USA | 0 |
NCT03121417 | Phase II | Nivolumab | Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT03122717 | Phase I | Gefitinib + Osimertinib | Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | Active, not recruiting | USA | 0 |
NCT03123783 | Phase Ib/II | Nivolumab + Sotigalimab | CD40 Agonistic Antibody APX005M in Combination With Nivolumab | Completed | USA | ESP | 0 |
NCT03130764 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC | Withdrawn | 0 | |
NCT03131037 | Phase I | AdV-tk + Valacyclovir | Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03131206 | Phase Ib/II | Alectinib | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | Terminated | USA | 0 |
NCT03132922 | Phase I | afamitresgene autoleucel | MAGE-A4c1032T for Multi-Tumor | Active, not recruiting | USA | CAN | 0 |
NCT03137771 | Phase II | Docetaxel Pemetrexed Disodium Gemcitabine Erlotinib | Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | Active, not recruiting | USA | ISR | CAN | 1 |
NCT03138889 | Phase Ib/II | NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | Terminated | USA | FRA | ESP | DEU | AUS | 0 |
NCT03141359 | Phase II | Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide | Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC | Active, not recruiting | USA | 0 |
NCT03148327 | Phase Ib/II | Durvalumab | Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy | Active, not recruiting | USA | AUS | 0 |
NCT03156114 | Phase I | Ezabenlimab Miptenalimab | This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. | Completed | USA | POL | GBR | ESP | CAN | 0 |
NCT03157128 | Phase Ib/II | Selpercatinib | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001) | Active, not recruiting | USA | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | AUS | 5 |
NCT03158129 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection | Active, not recruiting | USA | 0 |
NCT03158883 | Phase I | Avelumab | UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients | Completed | USA | 0 |
NCT03164616 | Phase III | Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel | Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) | Active, not recruiting | USA | POL | HUN | GBR | DEU | BRA | BGR | 12 |
NCT03164772 | Phase Ib/II | BI 1361849 + Durvalumab + Tremelimumab | Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC | Completed | USA | 0 |
NCT03166254 | Phase I | Pembrolizumab | Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer | Withdrawn | 0 | |
NCT03166631 | Phase I | BI 891065 + Ezabenlimab BI 891065 | A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread | Terminated | USA | 0 |
NCT03168464 | Phase Ib/II | Nivolumab | Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) | Terminated | USA | 0 |
NCT03170206 | Phase Ib/II | Palbociclib Binimetinib Binimetinib + Palbociclib | Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03175224 | Phase Ib/II | Vebreltinib | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) | Recruiting | USA | ITA | HUN | GBR | FRA | FIN | ESP | CAN | AUS | 4 |
NCT03177291 | Phase I | Carboplatin + Pemetrexed Disodium + Pirfenidone Carboplatin + Paclitaxel + Pirfenidone | Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC | Active, not recruiting | USA | 0 |
NCT03178071 | Expanded access | Lorlatinib | Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Harboring Specific Molecular Alterations | No longer available | USA | 0 |
NCT03178552 | Phase II | Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Divarasib Atezolizumab + Cobimetinib + Vemurafenib Alectinib | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 14 |
NCT03179436 | Phase Ib/II | MK-1308 + Pembrolizumab MK-1308 | Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | Completed | USA | SWE | POL | NZL | ITA | ISR | GRC | FRA | ESP | CAN | AUS | 5 |
NCT03181308 | Phase I | Carotuximab + Nivolumab | Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC | Completed | USA | 0 |
NCT03184571 | Phase II | Bemcentinib + Pembrolizumab | BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC | Completed | USA | NOR | GBR | ESP | 0 |
NCT03191149 | Phase II | Osimertinib | Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | Recruiting | USA | 0 |
NCT03191786 | Phase III | Atezolizumab Gemcitabine Vinorelbine | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS) | Completed | SVK | ROU | POL | LUX | ITA | IRL | GBR | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | ARG | 7 |
NCT03195491 | Phase III | Nivolumab | A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (CheckMate870) | Completed | 2 | |
NCT03197467 | Phase II | Pembrolizumab | Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer (NEOMUN) | Completed | DEU | 0 |
NCT03202940 | Phase Ib/II | Alectinib + Cobimetinib | A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC | Active, not recruiting | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03215706 | Phase III | Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) | Completed | USA | ROU | POL | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 5 |
NCT03215810 | Phase I | Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03217071 | Phase II | Pembrolizumab | Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03217669 | Phase I | Epacadostat + Sirolimus | Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | Active, not recruiting | USA | 0 |
NCT03220477 | Phase I | Guadecitabine + Mocetinostat + Pembrolizumab | Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. | Active, not recruiting | USA | 0 |
NCT03223155 | Phase I | Ipilimumab + Nivolumab | Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03224871 | Phase I | Pembrolizumab Aldesleukin Nivolumab | A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. | Completed | USA | 0 |
NCT03225664 | Phase Ib/II | Pembrolizumab Pembrolizumab + Trametinib | BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT03228186 | Phase II | Docetaxel + MLN4924 | Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT03228667 | Phase II | Nivolumab + Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept + Pembrolizumab | QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy | Recruiting | USA | 0 |
NCT03232892 | Phase II | Trametinib | Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT03233724 | Phase Ib/II | Pembrolizumab | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | Terminated | USA | 0 |
NCT03236935 | Phase I | L-NMMA + Pembrolizumab | Phase Ib of L-NMMA and Pembrolizumab | Active, not recruiting | USA | 0 |
NCT03237377 | Phase II | Durvalumab + Tremelimumab Durvalumab | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03239340 | Phase III | Osimertinib | A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib (ELIOS) | Completed | USA | ITA | ESP | 2 |
NCT03242915 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium | Pembrolizumab in Combination With Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Targetable Genetic Alterations, Previously Treated With Appropriate Targeted Agents, With Progressive Disease | Active, not recruiting | USA | 0 |
NCT03247309 | Phase I | Aldesleukin + IMA201 Cyclophosphamide + Fludarabine | TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) | Completed | USA | DEU | 0 |
NCT03255083 | Phase I | DS-1205c + Osimertinib | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Terminated | 1 | |
NCT03256136 | Phase II | Carboplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab | A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03257722 | Phase Ib/II | Idelalisib + Pembrolizumab | Pembrolizumab + Idelalisib for Lung Cancer Study | Terminated | USA | 0 |
NCT03260491 | Phase I | Patritumab deruxtecan | U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer | Recruiting | USA | NLD | ESP | 3 |
NCT03262779 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. | Completed | USA | 0 |
NCT03265080 | Phase I | ADXS-NEO | Expressing Personalized Tumor Antigens Study | Terminated | USA | 0 |
NCT03268057 | Phase Ib/II | Avelumab + Pepinemab | VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT03270176 | Phase I | Avelumab + Xevinapant | A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy | Completed | ROU | POL | CAN | 0 |
NCT03274479 | Phase I | PBF-1129 | PBF-1129 in Patients With NSCLC | Active, not recruiting | USA | 0 |
NCT03275597 | Phase I | Durvalumab + Tremelimumab | Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition | Terminated | USA | 0 |
NCT03285321 | Phase II | Ipilimumab + Nivolumab Nivolumab | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT03285763 | FDA approved | Atezolizumab | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (TAIL) | Completed | SWE | SVN | POL | NLD | LVA | LBN | ITA | GRC | GBR | ESP | DNK | BRA | ARG | 11 |
NCT03286296 | Phase I | LZM009 | LZM009 to Treat Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03289962 | Phase I | Autogene cevumeran Atezolizumab + Autogene cevumeran | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | SWE | NLD | GBR | ESP | DEU | CAN | BEL | 0 |
NCT03292133 | Phase II | Gefitinib + Nazartinib | A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03299088 | Phase I | Pembrolizumab + Trametinib | Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations | Active, not recruiting | USA | 0 |
NCT03302234 | Phase III | Pembrolizumab Ipilimumab + Pembrolizumab | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) | Completed | USA | TUR | POL | LVA | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 9 |
NCT03302247 | Phase II | Nivolumab Gemcitabine + Nivolumab | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | Terminated | USA | 0 |
NCT03307759 | Phase I | Pembrolizumab | Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (SABRseq) | Completed | CAN | AUS | 0 |
NCT03308942 | Phase II | Niraparib Niraparib + Pembrolizumab Dostarlimab-gxly + Niraparib | Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants | Completed | USA | 0 |
NCT03311334 | Phase I | Atezolizumab + DSP-7888 DSP-7888 + Nivolumab | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors | Terminated | USA | CAN | 0 |
NCT03311672 | Phase II | Pembrolizumab | T-Cell PET Imaging With [18F]F-AraG in Lung Cancer | Withdrawn | 0 | |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) | Recruiting | USA | GBR | AUS | 1 |
NCT03313804 | Phase II | Pembrolizumab Atezolizumab Nivolumab | Priming Immunotherapy in Advanced Disease With Radiation | Active, not recruiting | USA | 0 |
NCT03317496 | Phase II | Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | Terminated | USA | ITA | HUN | GBR | ESP | CZE | CAN | AUS | 0 |
NCT03318939 | Phase II | Poziotinib | Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | Terminated | USA | NLD | ITA | ISR | FRA | ESP | CAN | BEL | 0 |
NCT03319628 | Phase I | XMT-1536 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Active, not recruiting | USA | 0 |
NCT03322540 | Phase II | Pembrolizumab Epacadostat + Pembrolizumab | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | Completed | USA | TUR | POL | ITA | ISR | IRL | GBR | EST | ESP | DNK | CHE | CAN | AUS | 5 |
NCT03322566 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Epacadostat + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab Cisplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium | A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | Completed | USA | TUR | ITA | ISR | IRL | HUN | GBR | ESP | CAN | AUS | 4 |
NCT03325166 | Phase II | Pembrolizumab | Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases | Terminated | USA | 0 |
NCT03326752 | Phase I | DV281 | Phase 1b Dose Escalation and Dose Expansion Trial | Completed | USA | 0 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03330405 | Phase II | Avelumab + Talazoparib | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | Terminated | USA | HUN | GBR | DNK | CAN | BEL | AUS | 2 |
NCT03333343 | Phase I | LXH 254 + Nazartinib Nazartinib + Trametinib Gefitinib + Nazartinib Nazartinib + Ribociclib Capmatinib + Nazartinib | Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | Active, not recruiting | ITA | DEU | CAN | 3 |
NCT03334617 | Phase II | Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab | Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON) | Active, not recruiting | USA | ISR | FRA | ESP | DEU | CAN | AUT | 1 |
NCT03337698 | Phase Ib/II | Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Ciforadenant Atezolizumab Atezolizumab + Docetaxel Docetaxel Atezolizumab + Cobimetinib Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + RO6958688 | A Study Evaluating ThA Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus Lung) | Active, not recruiting | USA | ISR | GBR | FRA | ESP | AUS | 2 |
NCT03343613 | Phase I | LY3300054 + LY3381916 LY3381916 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | Terminated | USA | ITA | FRA | ESP | DNK | BEL | 0 |
NCT03345810 | Phase II | Gemcitabine + Vinorelbine Carboplatin + Nab-paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Durvalumab + Gemcitabine + Vinorelbine | Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (DURATION) | Completed | DEU | 0 |
NCT03348904 | Phase III | Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Epacadostat + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT03353675 | Phase II | MVA-MUC1-IL2 vaccine + Nivolumab | A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | HUN | FRA | BEL | 0 |
NCT03361228 | Phase Ib/II | Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03366766 | Phase II | Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium | Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery | Completed | USA | 0 |
NCT03367819 | Phase Ib/II | Isatuximab Cemiplimab + Isatuximab | Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies | Terminated | USA | ITA | GBR | FRA | 1 |
NCT03371992 | Phase I | Nivolumab | Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NO3DEXPL) | Unknown status | USA | 0 |
NCT03377023 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nintedanib + Nivolumab | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03379441 | Phase II | Pembrolizumab | Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC (MP-LALC) | Unknown status | ITA | 0 |
NCT03380871 | Phase I | Carboplatin + NEO-PV-01 + Pembrolizumab + Pemetrexed Disodium + Poly ICLC | A Personalized Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | Completed | USA | 0 |
NCT03381274 | Phase Ib/II | AZD4635 + Oleclumab Oleclumab + Osimertinib | Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study | Active, not recruiting | USA | 2 |
NCT03382899 | Phase II | Pegilodecakin + Pembrolizumab Pembrolizumab | Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 1)mall Cell Lung Cancer (Cypress 1) | Terminated | USA | 0 |
NCT03382912 | Phase II | Nivolumab + Pegilodecakin Nivolumab | Study of AM0010 With NivolumabStudy of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 2) | Terminated | USA | 0 |
NCT03383302 | Phase Ib/II | Nivolumab | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects (STILE) | Active, not recruiting | GBR | 0 |
NCT03386929 | Phase Ib/II | Avelumab + Axitinib + Palbociclib | Survival Prolongation by Rationale Innovative Genomics (SPRING) | Terminated | USA | LUX | ISR | ESP | 0 |
NCT03387111 | Phase Ib/II | Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 | Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy | Terminated | USA | 0 |
NCT03391869 | Phase III | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03392246 | Phase II | Osimertinib + Selumetinib | A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | Active, not recruiting | USA | 0 |
NCT03396211 | Phase I | Nivolumab + Rivoceranib | Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer | Completed | USA | 0 |
NCT03396497 | Phase I | LYC-55716 + Pembrolizumab | Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer | Unknown status | USA | 0 |
NCT03401385 | Phase I | Datopotamab deruxtecan | First-in-human Study of DS-1062a for Advanced Solid Tumors | Active, not recruiting | USA | 1 |
NCT03409458 | Phase Ib/II | Avelumab + Imifoplatin | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) | Completed | USA | CHE | 0 |
NCT03410043 | Phase II | Osimertinib | Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study | Active, not recruiting | USA | 0 |
NCT03410927 | Phase Ib/II | TAS0728 | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | Terminated | USA | GBR | FRA | ESP | 0 |
NCT03412877 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer | Recruiting | USA | 0 |
NCT03415126 | Phase I | ERAS-007 | A Study of ASN007 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03416335 | Phase Ib/II | DSP-0509 DSP-0509 + Pembrolizumab | A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Terminated | USA | 0 |
NCT03417037 | Phase III | Linrodostat + Nivolumab | An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer | Withdrawn | USA | TUR | ITA | GRC | FRA | ESP | DEU | CZE | CHE | CAN | BRA | AUT | AUS | 4 |
NCT03417882 | Phase II | GRN-1201 + Pembrolizumab | GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC | Terminated | USA | 0 |
NCT03418532 | Phase Ib/II | MP0250 | MP0250 DARPin Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC | Terminated | USA | 0 |
NCT03419559 | Phase II | LN-145 Durvalumab + LN-145 | Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combo With Durvalumab in Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT03425006 | Phase II | Itacitinib + Pembrolizumab | Pembrolizumab and Itacitinib (INCB039110) for NSCLC | Terminated | USA | 0 |
NCT03425279 | Phase Ib/II | Mecbotamab Vedotin | CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors | Active, not recruiting | USA | 2 |
NCT03425331 | Phase II | Ipilimumab + Nivolumab | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | Terminated | USA | 0 |
NCT03425643 | Phase III | Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | Active, not recruiting | USA | ROU | POL | LVA | LTU | ITA | IRL | GBR | FRA | EST | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 8 |
NCT03430063 | Phase II | Cemiplimab + Ipilimumab Cemiplimab | A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer | Terminated | USA | POL | GBR | FRA | ESP | DEU | BEL | 2 |
NCT03433469 | Phase II | Osimertinib | Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery | Active, not recruiting | USA | 0 |
NCT03434418 | Phase II | Osimertinib | A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations | Completed | USA | 0 |
NCT03435250 | Phase I | AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | Terminated | USA | FRA | ESP | 0 |
NCT03438318 | Phase I | Atezolizumab + Vidutolimod | Study Evaluating CMP-001 in Combination With Atezolizumab in Subjects With Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03446417 | Phase I | ZN-e4 | A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer | Completed | USA | 1 |
NCT03446547 | Phase II | Durvalumab | Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) (ASTEROID) | Recruiting | SWE | NOR | FIN | 0 |
NCT03447769 | Phase III | Canakinumab | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: (None) | Terminated | USA | TUR | SVN | ROU | POL | NOR | LBN | ITA | ISR | ISL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | AUT | ARG | 18 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab Ciforadenant + CPI-006 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Completed | USA | AUS | 0 |
NCT03455556 | Phase Ib/II | Anetumab ravtansine + Atezolizumab | Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT03455829 | Phase Ib/II | Osimertinib G1T38 + Osimertinib | G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03456063 | Phase III | Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium Atezolizumab + Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium | A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) | Active, not recruiting | USA | SWE | SVN | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CHE | BRA | AUT | AUS | 9 |
NCT03456076 | Phase III | Cisplatin Alectinib Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | Active, not recruiting | USA | TUR | ROU | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | AUT | AUS | 12 |
NCT03468985 | Phase II | Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT03469960 | Phase III | Ipilimumab + Nivolumab | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE) | Active, not recruiting | FRA | 0 |
NCT03472560 | Phase II | Avelumab + Axitinib | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) | Terminated | USA | POL | ITA | HUN | ESP | 3 |
NCT03473925 | Phase II | Navarixin + Pembrolizumab | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | Completed | USA | ISR | CAN | AUS | 1 |
NCT03474497 | Phase Ib/II | Aldesleukin + Pembrolizumab + Radiotherapy | Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | Recruiting | USA | 0 |
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT03485209 | Phase II | Tisotumab vedotin-tftv | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 1 |
NCT03497767 | Phase II | Osimertinib | A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN) | Completed | AUS | 1 |
NCT03502330 | Phase I | Cabiralizumab + Nivolumab + Sotigalimab Cabiralizumab + Sotigalimab | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | Completed | USA | 0 |
NCT03504488 | Phase Ib/II | BA3021 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors | Completed | USA | POL | GRC | ESP | 2 |
NCT03505710 | Phase II | Trastuzumab deruxtecan | DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer (DESTINY-Lung01) | Completed | USA | NLD | FRA | ESP | 1 |
NCT03509012 | Phase I | Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) | Completed | USA | ESP | 3 |
NCT03515629 | Phase III | Cemiplimab + Ipilimumab Pembrolizumab | REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | Terminated | USA | LTU | ITA | 0 |
NCT03515837 | Phase III | Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Cisplatin + Pemetrexed Disodium | Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) | Completed | USA | SWE | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 6 |
NCT03516214 | Phase I | Nazartinib + Trametinib | EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations (EATON) | Completed | ESP | DEU | 0 |
NCT03516981 | Phase II | MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | Active, not recruiting | USA | POL | ITA | IRL | GBR | ESP | CHE | CAN | AUS | 7 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03520686 | Phase III | Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab | QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. | Active, not recruiting | USA | 0 |
NCT03520842 | Phase II | Methotrexate + Regorafenib | Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03521154 | Phase III | Osimertinib | A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA) | Active, not recruiting | USA | TUR | HUN | ESP | BRA | ARG | 11 |
NCT03525795 | Phase Ib/II | CPI-1205 + Ipilimumab | ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03526887 | Phase II | Pembrolizumab | Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay) | Completed | ESP | 0 |
NCT03527108 | Phase II | Nivolumab + Ramucirumab Nivolumab | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | Recruiting | USA | 0 |
NCT03535363 | Phase I | Osimertinib | Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC | Completed | USA | 0 |
NCT03535740 | Phase II | Brigatinib | A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2) | Completed | USA | SWE | NLD | ITA | FRA | ESP | DEU | CAN | AUT | AUS | 5 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03539536 | Phase II | Telisotuzumab vedotin | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BGR | BEL | AUS | 6 |
NCT03546361 | Phase I | Ad-CCL21-DC Ad-CCL21-DC + Pembrolizumab | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03559049 | Phase Ib/II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + Rucaparib | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03563716 | Phase II | Atezolizumab + Tiragolumab Atezolizumab | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Active, not recruiting | USA | FRA | ESP | 3 |
NCT03565445 | Phase I | ASP1948 + Nivolumab ASP1948 | A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | CAN | 4 |
NCT03567642 | Phase I | Carboplatin + Etoposide + Osimertinib Cisplatin + Etoposide + Osimertinib | A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers | Active, not recruiting | USA | 0 |
NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Completed | USA | 0 |
NCT03568656 | Phase Ib/II | Atezolizumab + CCS1477 CCS1477 CCS1477 + Olaparib CCS1477 + Darolutamide Abiraterone + CCS1477 CCS1477 + Enzalutamide | Study to Evaluate CCS1477 in Advanced Tumours | Recruiting | USA | SWE | NLD | GBR | FRA | ESP | 0 |
NCT03573947 | Phase II | Ipilimumab + Nivolumab + Paclitaxel | Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (TOP1705) | Completed | USA | 0 |
NCT03574220 | Phase I | Pembrolizumab | Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer | Withdrawn | 0 | |
NCT03574649 | Phase II | Carboplatin + Cisplatin + Docetaxel + Paclitaxel Aldoxorubicin + Avelumab + Cisplatin + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6301 + haNK cells + Nogapendekin alfa inbakicept + Paclitaxel | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT03580694 | Phase I | Cemiplimab + REGN4659 Cemiplimab | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT03581487 | Phase Ib/II | Durvalumab + Selumetinib + Tremelimumab | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03583086 | Phase Ib/II | Nivolumab + Vorolanib | H I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | Completed | USA | 0 |
NCT03586453 | Phase II | Osimertinib | Osimertinib In EGFR Mutant Lung Cancer | Active, not recruiting | USA | 0 |
NCT03588039 | Phase I | Oraxol + Pembrolizumab | Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03589547 | Phase II | Durvalumab | Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung | Active, not recruiting | USA | 0 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Completed | USA | 0 |
NCT03595059 | Phase I | Docetaxel + Mirzotamab clezutoclax Mirzotamab clezutoclax + Paclitaxel Mirzotamab clezutoclax | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | Active, not recruiting | USA | NLD | ISR | ESP | CAN | AUS | 4 |
NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Completed | USA | CAN | 1 |
NCT03596866 | Phase III | Brigatinib Alectinib | A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3) | Completed | USA | SWE | ROU | ITA | HRV | GRC | FRA | ESP | DEU | CAN | AUT | ARG | 8 |
NCT03600701 | Phase II | Atezolizumab + Cobimetinib | Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03608020 | Phase Ib/II | BMX-001 | A Trial for Treatment |